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FOREWORD 
“I'd unravel any riddle, For any individ'le, In trouble or in pain (…) 
I would dance and be merry, Life would be a ding-a-derry, If I only had a brain” 
- From “If I only had a brain” by Harold Arlen & E.Y. Harburg (The Wizard of Oz, 1939) 
Usually, when the brain is depicted by artists, it’s in association with feelings, thinking, 
dreaming, intelligence and other psychological features. Consider, for instance, the 
poem “The brain is wider than the sky” by Emily Dickinson or the cartoon “Pinky and 
the Brain” from the 1990’s. The body’s movements are perhaps more associated with 
features like strength and organs like the skeleton and muscles. Of course, the brain’s 
role in movement is just as important. An artistic exception is the song “If I only had a 
brain” from the Wizard of Oz. It’s sung by the Scarecrow who Dorothy meets on the 
way to Oz, and he’s imagining all the things he would do if he had a brain, including 
not only solving riddles and thinking thoughts, but also dancing – clearly a movement 
that you need the brain to perform. Perhaps the song writers intended dancing to just 
be an expression of joy and not a task that you need the brain for, but it doesn’t 
matter.  
One needs the brain to move and to think, but having a brain means that you are also 
vulnerable to diseases of the brain. This thesis is about trying to understand some of 
the causes of Parkinson’s disease, a movement disorder, but it’s also about dementia, 
a disorder of cognition. My reason for wanting to study these diseases is because they 
are devastatingly debilitating to the patients but also to the families of those affected 
and there are so many things we don’t yet understand about them. 
A few words about the structure of the thesis; it is meant to be a complement to the 
published constituent papers which are reprinted in the back and I have thus 
attempted to repeat as little as possible of the published texts. If it feels like a 
daunting task to read the whole thing, don’t worry; researchers rarely read entire 
articles not to mention whole theses. There are lots of diagrams and pictures, I won’t 
mind if you just look at them. I’m just happy that you reached the end of this 
foreword. 
 
Sine Metu, 
 
 
 
AD 2013 
AM 5774  
AKI 202 
SAS 19693 
SAMMANFATTNING PÅ SVENSKA 
Kroppens rörelser, som det mina fingrar gör när de skriver den här texten på datorns 
tangentbord, utförs av muskler styrda av impulser från centrala nervsystemet via 
perifera nervsystemet. Centrala och perifera nervsystemen utgörs av enorma nätverk 
av nervceller, där varje enskild cell består av en cellkropp med korta utskott 
(dendriter) och långa utskott (axon). Dessa celler kommunicerar med varandra genom 
att olika signalmolekyler (neurotransmittorer) utsöndras från en nervcells utskott och 
reagerar med specialiserade mottagare (receptorer) på en annan nervcells yta. Högst 
upp i hjärnstammen, i mellanhjärnan, sitter substantia nigra där specialiserade 
nervceller producerar neurotransmittorn dopamin, vilken behövs bl.a. för att initiera 
och styra rörelser i centrala nervsystemet. I Parkinsons sjukdom dör (degenererar) 
dessa nervceller vilket leder till lokal brist på dopamin med påverkan på 
rörelseförmågan som en konsekvens. Patienter som drabbas av Parkinsons sjukdom 
lider bl.a. av skakningar, stelhet och ovanligt långsamma rörelser. Symptomen börjar 
ofta på en sida av kroppen och förvärras successivt tills det blir ett allvarligt 
handikappande tillstånd. Förekomsten av Parkinsons sjukdom är vanligast över 65 års 
ålder och upp till ca. 1% av populationen är drabbad. Man har hittat flera gener som 
medför ökad risk för Parkinsons sjukdom, men det är bara en mycket liten andel av 
patienterna vars sjukdom kan förklaras helt av ärftliga faktorer. De flesta fallen 
orsakas av ett samspel mellan olika ärftliga och miljömässiga riskfaktorer, av vilka de 
flesta än så länge är okända. Det starkaste dokumenterade sambandet mellan en 
riskfaktor och Parkinsons sjukdom är en skyddande effekt av rökning, dvs. att de som 
röker har lägre risk att drabbas jämfört med de som inte röker. Andra riskfaktorer som 
har studerats och föreslagits ha ett samband med ökad risk av Parkinsons sjukdom är 
bl.a. bekämpningsmedel inom jordbruk, mjölkprodukter och metaller.  
Förutom nedsatt rörelseförmåga utvecklar patienter med Parkinsons sjukdom, oftare 
än friska personer, även demens, dvs. nedsatt kognitiv förmåga som karakteriseras av 
problem med framför allt minne, koncentration och uppfattningsförmåga. Det finns 
två troliga hypoteser som kan förklara varför Parkinsonpatienter drabbas av demens: 
1) den skada som drabbar dopaminproducerande nervceller i mellanhjärnar ”sprider 
sig” till andra delar av hjärnan som styr kognitiv funktion, och 2) samma ärftliga 
och/eller miljömässiga riskfaktorer som orsakar neurodegenerationen i mellanhjärnan 
leder också till neurodegenerationen i de andra delarna av hjärnan som har att göra 
med kognitiv funktion.  
Det övergripande målet med den här avhandlingen var att öka förståelsen för vad som 
orsakar Parkinsons sjukdom och varför patienter med Parkinsons sjukdom drabbas av 
demens.  
Mycket epidemiologisk forskning i Sverige och i andra länder bedrivs med data 
insamlade för andra ändamål än forskning, inklusive administrativa register inom 
sjukvården. I studie I undersöktes tillförlitligheten av Parkinsondiagnoser från svenska 
   
Patientregistret och Dödsorsaksregistret i epidemiologiska studier. Som ”gold 
standard”, dvs. den bästa möjliga tillgängliga diagnosen, användes uppgifter från en 
storskalig undersökning av över 35000 tvillingar som var 50 år eller äldre under åren 
1998-2004. Resultatet visade att bland de som hade Parkinsons sjukdom som 
huvuddiagnos från minst en sjukhusvistelse registrerad i Patientregistret, kunde 83.0% 
av fallen bekräftas av gold standard (det positiva prediktiva värdet). Motsvarande 
siffra för dödsorsaksregistret var 80.0%. De flesta fallen som feldiagnosticerades i 
registrena led av sjukdomar som är snarlika Parkinsons sjukdom och som också 
drabbar rörelseapparaten (parkinsonismsjukdomar). Av alla Parkinsonfall 
detekterades 50.0% i patientregistret någon gång under sitt liv (sensitiviteten). 
I studie II undersöktes sambandet mellan risken för Parkinsons sjukdom och 14 olika 
yrkesmässiga exponeringar bland över 14000 manliga tvillingar som deltog i 
enkätstudier under 1960- och 1970-talet, och sedan följdes upp i svenska hälsoregister 
under sammanlagt 43 år. Huruvida männen var exponerade mättes genom en matris 
som uppskattade sannolikheten för att vara utsatt för olika kemiska ämnen i sitt yrke. 
Resultaten visade en 63% ökad risk (hazardkvot 1.63 (95% konfidensintervall: 1.09-
2.44)) för Parkinsons sjukdom bland de som exponerats för ickeorganiskt damm i 
vilket en stor grupp ämnen ingår, bl.a. vägdamm från trafikerade stadsgator. Inget 
samband sågs mellan Parkinsons sjukdom och de 13 andra yrkesmässiga 
exponeringarna som undersöktes, där bl.a. bekämpningsmedel inom jordbruk ingick.  
Studie III och IV syftade båda till att undersöka huruvida det är troligt att det finns 
gemensamma ärftliga och/eller miljömässiga faktorer som delas inom familjer (p.g.a. 
delad livsstil, etc.) som kan orsaka både Parkinsons sjukdom och demens. Ett sätt att 
angripa den här forskningsfrågan är att undersöka om dessa sjukdomar ansamlas i 
familjer, dvs. om de förkommer tillsammans bland förstagradssläktingar (helsyskon 
eller föräldrar och barn) oftare än vad som skulle vara väntat. Studie III är en 
systematisk översiktsartikel (review) där resultat från 16 publicerade studier om 
sambandet mellan risk för demens och att ha familjemedlemmar med Parkinsons 
sjukdom, eller risk för Parkinsons sjukdom och att ha familjemedlemmar med demens, 
sammanställdes i en metaanalys. I studie IV undersöktes samma samband bland över 
2 miljoner svenska invånare med information om släktskap från 
flergenerationsregistret och sjukdomsstatus från hälsoregister. Resultaten från studie 
III visade en 18% högre risk att få demens bland förstagradssläktingar till personer 
med Parkinsons sjukdom jämfört med de som inte har Parkinsons sjukdom i familjen 
(hazardkvot 1.18 (95% konfidensintervall: 1.00-1.39). Resultaten från studie IV visade 
att bland syskon till personer med Parkinsons sjukdom är det motsvarande 20% högre 
risk att drabbas av demens (hazardkvot 1.20 (95% konfidensintervall: 1.02-1.41)). 
Slutsatsen är därmed att det finns en liten ansamling av dessa två sjukdomar i familjer 
vilket innebär att Parkinsons sjukdom och demens sannolikt delar vissa riskfaktorer 
inom familjen, men att dessa delade riskfaktorer (dvs. hypotes 2 ovan) inte helt kan 
förklara varför patienter med Parkinsons sjukdom i så stor utsträckning drabbas av 
demens själva. 
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1 GENERAL INTRODUCTION TO EPIDEMIOLOGY 
There is unfortunately a very common misunderstanding about epidemiology; 
(Medical) epidemiology is the study of diseases or other medical or health-related 
outcomes on the population level, it is not the study of epidemics. In other words, 
epidemiology includes, but is not limited to, the study of communicable disease that 
may cause epidemics. Non-medical epidemiology also exists, for instance social 
epidemiology, which often employs the same methods as medical epidemiology but 
may study other types of outcomes and exposures. One way of defining 
epidemiological studies is like this: Studies where the unit of analysis is always a 
human being (not a mouse or a cell sample, etc.) and where the research question 
concerns something on the population level (not case studies, etc.). Note that 
epidemiology is a quantitative science as opposed to a qualitative science, and that 
this broad definition includes many studies where the investigators themselves may 
not consider the study to be an epidemiological study, but perhaps in many cases they 
should. 
When we talk about the epidemiology of an outcome, we usually talk about two main 
aspects; the distribution of the outcome in the population (descriptive epidemiology) 
and the relation between the outcome and potential risk factors (analytical 
epidemiology). Descriptive epidemiology concerns the occurrence of an outcome (e.g. 
a disease), usually in terms of prevalence (the proportion affected in a population at a 
given time), incidence (the rate of emergence of new cases over time), absolute 
numbers of affected persons, and distribution of affected persons over population 
characteristics such as age, sex and race. Analytical epidemiology concerns the 
association between an outcome and other variables (e.g. risk factors), referred to as 
exposures. In the epidemiological sense, an exposure can be a behavior or 
characteristic which may seem elusive, such as educational level, neuroticism or a 
genotype, or it can be a potentially modifiable environmental factor, such as smoking 
or physical activity. Exposures may also be both causative and protective in relation to 
the outcome; it all depends on how they are defined. Analytical epidemiology is most 
often boiled down to some kind of an approximation of a relative risk of outcome in 
exposed compared to non-exposed persons. However, relative risks do not tell us 
anything about the overall population distribution of diseases or exposures and 
therefore both descriptive and analytical epidemiology is necessary in understanding 
the public health importance of risk factors. The majority of diseases have complex 
etiologies, meaning that several separate risk factors are needed to cause the disease, 
and these risk factors may vary between affected individuals. Even in diseases with 
known necessary risk factors, such as in the case of human papilloma virus infection in 
cervical cancer, there may still be contributory risk factors important to the etiology of 
the disease which influence who becomes affected or not, such as concurrent 
infection or cervical screening participation. 
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Another important distinction among analytical epidemiological studies is that 
between observational and interventional (experimental studies). Whether a study is 
observational or experimental refers to how the distribution of exposure in the study 
population is determined, whether it’s assigned by the study investigators, such as a 
disease treatment in a randomized control study (interventional), or self-selected, 
such as smoking (observational), or inherent, such as a genotype (also observational), 
etc. Some exposures are possible to study in both observational and experimental 
settings, such as physical activity, but many exposures cannot be assigned by 
investigators to study participants for ethical or practical reasons, such as socio-
economic status or head trauma. A third type of study is ecological studies, generally 
defined as studies that do not include person-level data (micro data), only aggregated 
data on populations. Finally, a word on retrospective vs. cross-sectional vs. 
prospective studies. These terms all refer to the timing of exposure in relation to the 
outcome. In a retrospective study, an exposure that occurred before the outcome is 
ascertained after the incidence of the outcome, whereas in a prospective study the 
exposure is ascertained before the incidence of the outcome. In a cross-sectional 
study the outcome and a current exposure are ascertained at the same time. 
 
1.1 CAUSAL INFERENCE 
In experimental studies the investigators can control the parameters of the study, 
including importantly the timing of the exposure in relation to the outcome. Thus, the 
investigators can hopefully reasonably well assume that any observed association 
between the exposure and outcome was caused by their intervention (discounting 
placebo effects, etc., which lie outside of the scope of this introduction). However, in 
observational studies there are often issues of uncertainty about the validity of the 
results due to, among other reasons, the fact that virtually all environmental 
exposures are non-randomly distributed in the population. Thus, when an association 
is observed in an observational study we must always ask ourselves: Is it causal? Is it 
plausible that if we had been able to, for instance, remove the exposure in the 
exposed group, had the risk of the outcome in that group then changed to become 
that of the non-exposed group? To complicate issues further, sometimes observed 
associations are partly or completely spurious, that is, artificially induced by the study 
design. To be able to tackle and communicate these issues in a systematic way we use 
the framework of causal inference and its visual representation: directed acyclical 
graphs (DAG, fig. 1.1).  
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The generic DAG in fig. 1.1 could be applied to various analyses, for instance, a study 
of the association between coffee drinking (exposure) and speed of thesis writing 
(outcome). An arrow between two factors indicates that these two factors are 
potentially associated and it gives us the assumed direction of association, but does 
not say anything about whether it is a positive or a negative association or the 
strength of the association. A confounder is a factor that causes the exposure and the 
outcome. For instance, time of day or the number of hours of sleep the previous night 
may cause both coffee drinking and thesis writing speed. Familial confounding is a 
term used for all factors that can be shared between family members, including both 
genetic and environmental exposures. Conditioning on a variable (by, for instance, 
statistical adjustment or stratification/exclusion) which closes the causal path through 
that factor is represented by drawing a solid box around the variable.  A mediator is a 
factor that lies in the causal path between exposure and outcome. There are 
practically always potential mediators between the exposure and outcome, but that 
does not mean that the exposure is not causal. For instance, coffee drinking causes a 
chain of physiological reactions (mediators) that in turn affect writing speed. A collider 
is something that is caused by the exposure and the outcome. For instance, stomach 
aches may be caused by both coffee drinking and thesis writing. Paths through 
colliders are closed, unless the collider is adjusted for in which case the path is 
opened, which may cause spurious associations. In every model there are potential 
unmeasured confounders of importance. In particular, you should always consider 
potential confounders between a mediator and the outcome if you intend to adjust 
for that mediator. The reason is that the previously closed path though that 
unmeasured confounder may then be opened and that could lead to a spurious 
association. Finally, often we cannot measure a true outcome precisely but rely on 
some kind of proxy measure that may have some degree of misclassification (the 
same is true for all other variables in the model). It’s important to consider what the 
impact of an imprecise measure is on the association and whether there may be 
differential misclassification with regards to the other variables in the model.  
Fig. 1.1. Illustration of concepts in causal inference and its visual representation Directed 
Acyclical Graphs (DAG). 
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2 BACKGROUND 
2.1 THE BRAIN 
Together with the spinal cord, the brain makes up the central nervous system in 
humans. The brain is divided into two symmetrical hemispheres, the cerebellum and 
the brain stem (fig 2.1). The cerebral cortex of the hemispheres is further divided into 
four lobes, each with several specific functional regions. For instance, the primary 
motor cortex from which movement is controlled is located in the pre-central section 
of the frontal lobe. Memory is stored and processed in the temporal lobe. Visual input 
is processed in the occipital lobe and language and sensory input is processed in the 
parietal lobe.1 The brain stem connects the spinal cord with the brain and it is divided 
into the medulla, pons and mecencephalon (midbrain). Throughout the brain and 
brain stem are several specialized nuclei such as the highly connected basal ganglia 
which include the subthalamic nucleus, globus pallidus, nucleus accumbens, 
substantia nigra, and the striatum comprised of the caudate nucleus and putamen. 
Surrounding the brain and spinal cord and every blood vessel in the central nervous 
system is a layer of specialized endothelial cells which separate the normal circulation 
from the cerebrospinal fluid and neuronal tissue. This is called the blood-brain barrier 
and it protects the central nervous system from microorganisms and molecules that 
could be harmful. Neurons in the central and peripheral nervous systems have short 
and/or long outgrowths called dendrites and axons, allowing them to form pathways 
and networks and communicate across sometimes long distances. The interface 
between two neurons is called a synapse; there the pre-synaptic neuron releases 
signal molecules called neurotransmitters which react with receptors on the surface of 
the post-synaptic neuron causing an action potential which propagates the signal 
further.  
Fig. 2.1. Illustration of a sagittal brain section. Left hemisphere 
pictured. Original illustration of brain by Johannes Sobotta from 
Sobotta’s Atlas of Human Anatomy (1908).  
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2.2 PARKINSON’S DISEASE 
2.2.1 Clinical symptoms and diagnosis 
Parkinson’s disease (PD) is a movement disorder named after the James Parkinson 
who wrote “An Essay on the Shaking Palsy” in 1817, in which he described a group of 
cases with several distinct symptoms.2,3 Today three cardinal features together 
referred to as parkinsonism are recognized in PD4: 
1. Resting tremor 
Otherwise known as involuntary shaking or oscillations of the limbs or other 
parts of the body when in a resting position, such as sitting down with the 
hands resting on the lap. This is different from action tremor, which is 
involuntary shaking during different types of movement.  
2. Rigidity 
Hypertonia or stiffness due to too much muscle tone which makes the joints of 
the arms and legs harder to move.  
3. Bradykinesia 
Unusually slow movements during, for instance, walking or using the hands 
and arms. 
The onset of these symptoms is typically asymmetrical in PD patients, i.e., one side of 
the body is affected first. Other symptoms include micrographia (unusually small 
handwriting), hypophonia (low voice) and less expressive facial features sometimes 
known as masking. Patients are often divided into two groups based on whether the 
most dominant symptom is either tremor or bradykinesia. PD is a chronic progressive 
disorder meaning that symptoms worsen over time often leading to a severely 
debilitating condition. 
The diagnosis of PD is divided into three levels of certainty4: 
1. Possible PD 
Presence of tremor or bradykinesia plus rigidity or asymmetrical onset of 
symptoms. In addition, the patient does not have any features that suggest an 
alternative cause of the symptoms such as the use of neuroleptic drugs, 
presence of dementia within one year of onset of motor symptoms or 
hallucinations or specific atypical motor impairment symptoms such as 
prominent postural instability or “freezing” early in the disease course.  
2. Probable PD 
After at least three years observation, if at least three of the four cardinal 
features (including asymmetric onset) are still present and there is a 
substantial and sustained response to PD medication (e.g. Levo-dopa and 
dopamine agonists). 
20 
3. Definite PD 
If a post-mortem neuropathological examination of a patient with probable PD 
shows presence of neurodegeneration in the substantia nigra and no signs of 
any other probable cause of parkinsonism. 
 
2.2.2 Neuropathology 
One of the ways that movement is controlled in the central nervous system is through 
the so called nigro-striatal pathway. The motor cortex sends signals to dopaminergic 
neurons in the substantia nigra in the midbrain which project into the striatum where 
the neurotransmitter dopamine causes an either excitatory or inhibitory signal 
depending on which type of dopamine receptor it binds to. The pathway continues via 
other brain nuclei back to the motor cortex and to the peripheral nervous system 
which is in contact with the muscles of the body.  
Neurodegeneration is the process of progressive loss of neurons in the central 
nervous system due to apoptosis. Apoptosis is controlled cell death which has an 
important function in physiology, but in neurodegeneration it is triggered abnormally. 
Depending on which part of central nervous system is affected, different functional 
domains are impaired. Neurodegeneration is coupled with the observation of 
pathological protein aggregates in or around the apoptotic and pre-apoptotic 
neurons. Thus, neurodegenerative diseases are sometimes referred to as 
proteinopathies (protein misfolding diseases) when this particular aspect is studied. 
The motor symptoms in PD are caused by the selective degeneration of the 
dopaminergic neurons in the substantia nigra leading to a depletion of dopamine in 
the striatum. In PD, the normally pre-synaptic soluble protein α-synuclein aggregates 
together with other proteins intra-cellularly into characteristic insoluble spherical and 
thread-like shapes called Lewy bodies and Lewy neurites after their discoverer Fritz 
Heinrich Lewy.5 In PD, Lewy bodies are found extensively in the dopaminergic neurons 
of the substantia nigra pars compacta, but also in many other parts of the central 
nervous system. According to the neuropathological staging of PD by Braak et al.,6 the 
disease process can be summarized in six stages, where each stage represents further 
spreading of Lewy body pathology in the central nervous system: 
1. Lesions found in the dorsal motor nucleus of the glossopharyngeal and vagal 
nerves (the medulla of the brain stem) 
2. Coeruleus-subcoeruleus complex (midbrain), and commonly also the anterior 
olfactory nucleus 
3. Substantia nigra (midbrain) 
4. Anteromedial temporal mesocortex (temporal lobes) 
5. High order sensory association areas and prefrontal fields (frontal and parietal 
lobes) 
6. First order sensory association areas, premotor areas, as well as primary 
sensory and motor fields (frontal and parietal lobes) 
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PD does not become symptomatic until the pathology reaches stage 3 or 4 (or higher), 
when the majority of the dopaminergic neurons in the nigro-striatal pathway have 
been lost. 
 
2.2.3 Parkinsonian disorders 
There are several neurological disorders with parkinsonism besides PD. Together with 
PD they are referred to as parkinsonian disorders and the differential diagnosis of 
these disorders is not always clear-cut.7 Parkinsonian disorders include: 
• Multiple Systems Atrophy (MSA)8 
Patients have parkinsonism with often prominent postural instability early in 
the disease course, cerebellar ataxia which is problems coordinating 
movements and autonomic problems such as bladder and erectile dysfunction. 
As in PD, Lewy bodies are found in the substantia nigra making MSA a 
synucleinopathy like PD. A part from neurodegeneration of the nigro-striatal 
pathway there is also degeneration of olivopontocerebellar structures in the 
pons of the brain stem and cerebellum in MSA.9  
• Progressive Supranuclear Palsy (PSP)10 
The prominent features of PSP is parkinsonism with early onset of postural 
instability and falls, vertical gaze palsy which is difficulty moving the eyes up 
and down and dysphagia or problems with swallowing. The prominent protein 
aggregation in PSP is due to hyperphosphorylated tau protein forming intra-
cellular neurofibrillary tangles, making PSP a tauopathy. 
• Corticobasal degeneration (CB)11 
CB or corticobasal syndrome is characterized by parkinsonism with specific 
cognitive and behavior disturbances, and it is sometimes grouped together 
with PSP and fronto-temporal lobar degeneration (FTLD) as the three 
conditions share features and can be difficult to differentiate. CB is a 
tauopathy like PSP. 
• Cerebrovascular parkinsonism (CvP)12  
CVP or just vascular parkinsonism is not primarily a neurodegenerative 
disorder but rather parkinsonism caused by white matter lesions due to small 
vessel disease and/or lacunar infarctions in the brain. Clinically CvP patients 
often present with parkinsonian symptoms in the lower body first. 
Lewy body dementia (LBD) and Parkinson’s disease dementia (PDD) are also 
parkinsonian disorders and these are described in section 2.2.5. 
There are also several other movement disorder which are not usually included in the 
parkinsonian syndrome, such as essential tremor (ET) and Huntington’s disease. 
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2.2.4 Epidemiology 
2.2.4.1 Occurrence 
The overall prevalence of PD in all age-groups is estimated at 0.3%.13 The incidence of 
PD is very rare before age 50 after which it increases sharply with each year of life, 
reaching an estimated prevalence of up to 4% over age 80.13 The incidence of PD is 
estimated at about 100/100,000 person-years (PYR) at 60-70 years and up to 
400/100,000 PYR over age 80.13 Based on a study by Elbaz et al.,14 the lifetime risk of 
developing PD is estimates at 2.0% and 1.3% for men and women, respectively. The 
lifetime risk of developing any parkinsonism is slightly higher, estimated at 4.4% for 
men and 3.7% for women.14 
 
2.2.4.2 Genetic risk factors 
Traditionally, there have been two main ways of quantitatively investigating if a 
disease with complex etiology has genetic risk factors: through the study of heritability 
(proportional contribution of heritable factors to the variance of a phenotype) based 
on differences between concordance in monozygotic (MZ) and dizygotic (DZ) twin 
pairs and through the study of familial aggregation. Due to the low prevalence of PD, it 
was for a long time difficult to study heritability as large twin populations are needed. 
Early studies did not detect any significant heritability leading to a conclusion that 
heritability for PD was low.15 However, a more powerful recent twin study in the 
Swedish Twin Registry (STR) was able to estimate heritability for PD at 34% and 
heritability for any parkinsonian disorder at 40%.16 Familial aggregation, defined as 
relative risk of disease associated with having affected first-degree relatives, has been 
studied extensively for PD and a meta-analysis based on the 6 most methodologically 
rigorous published studies estimated this relative risk at 2.9 (95% Confidence Interval 
(CI): 2.2-3.8).17 Although familial aggregation of this magnitude is a strong indicator of 
the presence of heritable genetic risk factors for PD, it could be explained in part by 
environmental factors shared within families. 
A recent review of genome-wide association data for PD reported that 11 loci have so 
far been linked with PD risk, including loci in the genes encoding α-synuclein (SNCA) 
and tau protein.18 In addition, a small proportion of PD patients have a disease caused 
by autosomal dominant or recessive genetic variants of which some are high 
penetrant mutations. One such autosomal dominant variant is a duplication or 
triplication of the SNCA gene causing overabundance of the protein in the brain.19 
 
2.2.4.3 Environmental and lifestyle risk factors 
The best established environmental risk factor for PD is smoking which has a strong 
protective effect. A meta-analysis of 48 studies estimated the relative risk of PD for 
ever vs. never smokers at 0.59 (95% CI: 0.54-0.63).20 This effect is consistent in both 
case-control and prospective cohort studies and there appears to also be evidence for 
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a dose-response relationship between increasing pack-years of smoking and 
decreased PD risk, which is one of several indications that the effect of smoking on PD 
is a true causal effect.  There are also plausible biological mechanisms as nicotine has 
a neuroprotective and stimulating effect on the dopaminergic system.21 Caffeine 
intake has similarly been associated with a reduced risk of PD consistently in both 
case-control and prospective studies with a meta-estimate based on 13 studies of 0.69 
(95% CI: 0.59-0.80) for PD risk among coffee drinkers vs. nondrinkers. An association 
between PD risk and head trauma was seen in several case-control studies, but was 
not confirmed in prospective cohort studies indicating that the observed association 
may have been due to reverse causation.22,23 With the possible exception of dairy 
intake which may be a risk factor for PD,24 no other dietary, lifestyle or environmental 
risk factors have been consistently associated with PD. 
 
2.2.4.4 Socioeconomic and occupational risk factors 
Although the evidence is not consistent, there are indications that higher education 
may be associated with increased PD risk.25-27 For specific occupations the evidence is 
likewise inconsistent, but nevertheless two types of occupations may be associated 
with PD risk: occupations associated with high education and high socioeconomic 
status, e.g., teachers and physicians,25,26,28 and occupations that are at high risk of 
exposure to pesticides, e.g. farmers.29,30 Specific pesticides have also been linked to 
PD in both epidemiological and animal studies, in particular the insecticide Rotenone 
and the herbicide Paraquat.31 In animal studies exposure to these pesticides causes 
selective degeneration of dopaminergic pathways and parkinsonism-like symptoms.32 
Both of these pesticides can cross the blood-brain barrier. Manganese exposure which 
is common in welders can lead to a condition called manganism which shares 
similarities with parkinsonism. However, there is no evidence that manganese 
exposure is associated with PD risk.33 
 
2.2.5 Comorbidity between parkinsonism and dementia 
Dementia is a syndrome of cognitive decline that can be caused by several different 
conditions, of which Alzheimer’s disease (AD) is the most common. Alzheimer’s 
disease is named after Alois Alzheimer who published a report about the 
neuropathology of AD in 1907.34 The features of dementia include decline of cognitive 
function, i.e. memory impairment, difficulty in learning new information, visio-spatial 
problems and attention problems, and sometimes psychiatric symptoms such as 
hallucinations. As in PD, the diagnosis of AD is based on clinical symptoms and 
absence of cause for exclusion such as movement impairment early in the disease 
course or atypical sudden onset of symptoms.35 AD is a neurodegenerative disease 
with wide-spread involvement in the central nervous system. The neuropathological 
process in AD appears to be initiated in and around the hippocampus in the temporal 
lobe and the primary protein aggregates are extracellular amyloid-β plaques and intra-
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cellular neurufibrillar tau tangles. In late stages of AD, macroscopic brain atrophy (loss 
of cortical matter) is present in addition to the wide-spread abnormal protein 
aggregation in the brain.36 Other types of non-AD dementia include vascular dementia 
(VaD), LBD and FTLD. Dementia can also occur secondary to PD as PDD or due to e.g. 
drug or alcohol abuse or a brain tumor. Overall, the lifetime risk of dementia has been 
suggested to be 10-12%,37 whereas the lifetime risk after age 65 is estimated at about 
20%.38,39 Based on twin studies, the heritability of AD is estimated at 79%.40 Most 
studies of familial aggregation of AD among first-degree relatives have been case-
control studies conducted more than 20 years ago and a meta-estimate of 7 such 
studies showed a relative risk of 3.5 (95% CI: 2.6-4.6) for AD associated with first-
degree family history of AD.41 
 
As described above, dementia is an exclusion criterion for PD and parkinsonism is an 
exclusion criterion for AD.4,35 When the onset of dementia is either before or within 
one year of parkinsonism, the diagnosis is LBD (sometimes called dementia with Lewy 
bodies).42 When the onset of dementia comes after a diagnosis of PD is set, the 
diagnosis is PDD. There is an ongoing debate on whether LBD and PDD are the same 
or two different conditions.43 Neuropathologically, LBD and PDD patients often exhibit 
characteristics common to both AD and PD such as Lewy bodies and neuritic plaques, 
although LBD patients may have more white matter atrophy than PDD patients and 
Fig. 2.2. Illustration of clinical overlap between parkinsonian disorders 
and dementia. AD: Alzheimer’s disease, CvP: Cerebrovascular 
parkinsonism, LBD: Lewy body dementia, PD: Parkinson’s  disease, PDD: 
Parkinson’s disease dementia. 
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some different clinical symptoms such as more often hallucinations.44,45 An illustration 
of the overlap between parkinsonian disorders and dementia is shown in fig. 2.2. 
For PD patients, the risk of developing dementia (i.e., progressing to PDD) is 
consistently found to be many times higher than for PD-free persons; the relative risk 
has been estimated at between 1.7 and 5.946 and 24.5% of PD patients are estimated 
to have dementia.47   
 
2.2.6 Familial coaggregation of Parkinson’s disease and dementia 
As described above, both PD and AD aggregate in families and commonly co-occur in 
individuals as comorbidity between parkinsonism and dementia. Thus, it has been 
hypothesized that these diseases also coaggregate in families, which would indicate 
that a cause of the co-occurrence of dementia and parkinsonism in individuals could 
be due to shared familial risk. The hypothesis is that familial (correlated) genetic or 
environmental risk factors may contribute to the etiology of both PD and dementia. 
Epidemiological studies that have investigated this hypothesis have been mainly case-
control48,49 or reconstructed cohort studies50-54 studying the association between AD 
or dementia and family history of PD and results have been largely inconclusive. In 
1991, Van Duijn et al. performed a meta-analysis of two early such case-control 
studies48,55 and they found evidence for familial coaggregation of these diseases; 
pooled odds ratio (OR) 2.4, 95% CI: 1.0-5.8 for risk of AD associated with family history 
of PD.41  
 
2.3 FAMILIAL AGGREGATION AND COAGGREGATION OF DISEASES 
Why do we study familial aggregation and coaggregation of disease at all? Originally 
such studies were performed to understand complex diseases, i.e. diseases without 
clear etiology such as mendelian inheritance (based on pedigrees) or infectious 
agents. Familial aggregation studies share an aim with heritability studies; to 
understand the general source of causes for complex diseases (or other phenotypes), 
and these two designs can be seen as complimentary. Generally, we expect complex 
diseases to aggregate in families to some extent, even if they have low or no 
heritability, as familial aggregation can be due to other reasons that shared genetic 
factors. However, the magnitude of aggregation is interesting and just as we study 
differences in concordance between relatives with varying degree of shared genes, we 
are interested in the difference in magnitude of aggregation between different types  
of biological of relatives, such as siblings, parents and offspring, MZ and DZ twins and 
non-biological relatives such as spouses and adopted siblings. An advantage of familial 
aggregation studies over heritability studies is that the interpretation of risks is 
somewhat easier to understand and communicate to patients and their families. 
The earliest familial aggregation studies appear to have been concerning different 
types of cancer. Below is a quote from a study about familial aggregation of breast 
cancer by Penrose et al.56 published in 1948: 
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“In spite of evidence brought forward by a great many 
observers that mammary cancer can frequently be found 
affecting several of the female members of a family group, 
doubt still remains as to whether heredity plays any significant 
aetiological part. This doubt arises because of the great 
prevalence of the disease in the general population, where it is 
responsible for nearly 3 percent of all female deaths. With so 
common a condition, it is difficult to demonstrate convincingly 
that the occasional familial concentration is not merely the 
result of a random distribution of cases.” 
Today we know that breast cancer is caused by both genetic and environmental 
factors, partly thanks to these early familial aggregation studies that showed that 
breast cancer was more common among women with family history of the disease 
than what would be expected by chance. 
Even if two diseases aggregate separately in families and co-occur in individuals to a 
large degree, we don’t necessarily expect them to show familial coaggregation too. 
There are examples from disease groups where co-occurrence and separate familial 
aggregation has corresponded to familial coaggregation of diseases, such as in bipolar 
disorder and schizophrenia,57 but also examples of disease groups where that was not 
case, such as in cryptorchidism, hypospadias and testicular germ cell cancer.58 When 
two complex diseases are found to coaggregate in families this indicates that they 
share genetic and/or environmental causes, and if the etiology of one of the diseases 
is better understood than the other than the presence of familial coaggregation may 
provide clues to the etiology of the other disease. However, if there is considerable 
co-occurrence of two disease but no or low familial coaggregation, this is an indication 
that the co-occurrence may be due to a direct causal effect of one disease on the 
other. 
 
2.3.1 Epidemiological definition 
Familial aggregation and coaggregation studies are studies of disease risk associated 
with family history of the same or another disease. The outcome or family history 
exposure does not strictly speaking have to be a disease; it can also be a physiological 
measurement, a behavior, a biomarker, etc. However, in this thesis I will discuss 
familial aggregation and coaggregation studies in the context of chronic diseases that 
are measured as binary variables. Typically outcomes and exposures in 
epidemiological studies are ascertained in the same person and thus familial 
aggregation and coaggregation studies pose a problem since the outcome and 
exposure must be ascertained in at least two related persons. Firstly, let’s define the 
different types of epidemiological designs possible when studying familial aggregation 
and coaggregation of diseases: 
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• Case-control 
Index cases with a certain outcome are compared for presence of the family 
history exposure to matched or otherwise sampled (index) controls. The 
outcome is prevalent or incident, depending on the method of case 
recruitment. The exposure is defined as family history of disease which can be 
either prevalent (presence of affected living relatives at the time) or, more 
commonly, prevalent/past (ever presence of any affected living or dead 
relatives). Sometimes different exposure levels are ascertained, such as family 
history in siblings, parents/offspring, second-degree relatives, etc., or 
none/one/two/more than two affected relatives. 
• Reconstructed cohort 
Relatives of index cases (exposed to family history of the cases’ disease) are 
compared for the presence of prevalent or incident disease to relatives 
(unexposed to family history) of (index) controls matched to the index cases or 
otherwise sampled. This is called a reconstructed cohort design because an 
exposed cohort is compared to an unexposed cohort, but the study persons 
(the relatives) are not themselves participants in the study. In fact, relatives 
who are dead at the time of the study may also be included as study persons. 
The outcome can be defined as prevalent (all relatives affected at the time of 
the study), but most often the outcome is retrospectively attempted to be 
ascertained as if it was incident and the cohorts are analyzed in a longitudinal 
manned (time-to-event analyses). The exposure is prevalent or incident 
disease, depending on the method of recruitment of the index cases.  
• Matched cohort 
Persons with family history of a disease (exposed cohort) are compared for 
presence or incidence of the outcome to persons without family history of that 
disease (unexposed cohort) who are matched to exposed relatives or 
otherwise sampled. The difference between this and a reconstructed cohort 
design is that here the relatives who experience the outcome are the 
participating study persons themselves. This study design does not involve 
index cases and controls and it’s practically a cohort study. Definition of 
outcome depends on whether the cohort is cross-sectional or followed-up 
prospectively. As in a case-control study, the exposure can be defined as either 
prevalent (all living relatives affected at the time) or, more commonly, 
prevalent/past (all living relatives affected at the time and all dead relatives 
affected at the time of their death).  
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• Cohort 
Study persons in a cohort are each ascertained for presence or absence of 
family history of disease (the exposure). The relatives that provide the family 
history exposure can also themselves be included in the cohort as study 
persons. Outcome and exposure defined as in a matched cohort study. (This is 
the design in study IV and IVtw). 
In a register-based setting, familial aggregation and coaggregation studies can be 
designed that share characteristics with both case-control and matched cohort 
studies. These are described further in the section on register-based research in 
section 4.1.4.1 
 
 
 
In fig. 2.3 a DAG of a possible model of the causal pathways in familial aggregation and 
coaggregation of two diseases is shown. This DAG is based on the model suggested by 
Hudson et al.59 This model assumes that the association between exposure disease in 
relatives (XR or YR) and outcome disease in study persons (X and Y) is caused by both 
familial factors unique to X and Y (FX and FY) and familial factors shared between the 
diseases (FX/Y). In addition, the study person and relatives have non-shared familial 
factors that may cause both diseases (C/CR). One way of looking at familial aggregation 
studies is that they are the search for FX or FY and familial coaggregation studies are 
the search for FX/Y. 
Fig. 2.3. Directed acyclical graph of causal pathways in familial 
aggregation and coaggregation studies. Subscript R’s indicate 
outcomes in relatives (on the left). Based on model by Hudson, et al.59 
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There are three primary problems that may affect familial aggregation and 
coaggregation studies: 
1. Multiple time-lines 
Regardless of which study design is employed, at least two time-lines are 
relevant for each observation; one for the outcome and one or several for the 
exposure. A “regular” epidemiological cohort study with one time-line for the 
exposure and one for the outcome would be called a time-varying exposure 
study and would be solved by having study persons potentially contribute both 
exposed and unexposed time. While this is theoretically possible and perhaps 
the most epidemiologically sound solution in longitudinal familial aggregation 
or coaggregation studies too, it’s problematic. Firstly, it is only possible if each 
study person only has one relative (see section on relative dyads below). 
Secondly, it can be seen as introducing an additional assumption to the causal 
model, namely the direct effect of a relative’s disease on the outcome; in fig. 
2.3, imagine an additional direct arrow from XR to Y. In some instances this is a 
sound assumption, for instance in the study of familial coaggregation of 
suicidal behavior and family history of psychiatric disease because we expect 
that having a relative with a psychiatric condition may have a direct effect on 
one’s own suicidal behavior. However, for neurological diseases this 
assumption is not supported. 
2. Information bias 
In most studies where the exposure is family history of a disease, 
ascertainment of either the exposure (case-control, matched cohort and 
cohort studies) or the outcome (reconstructed cohort studies) is dependent on 
information from study persons or index cases/controls or their proxies, which 
are most often spouses or biological relatives. Thus, there is often cause to 
suspect that reporting of disease history in relatives may be associated with 
disease status in the study persons.60 This source of bias is difficult to handle 
completely but it may be reduced by, for instance, studying the medical 
records of all living and deceased relatives or by confirming diagnoses in those 
that were reported as affected. 
3. Dependency of data 
In all study designs were multiple family members from the same families are 
included the data can be considered to be non-independent. This fact may bias 
the standard errors to appear smaller than they are. Luckily, there are several 
ways to statistically adjust standard errors in clustered data and thus reduce 
this source of bias. 
30 
3 AIMS 
The overarching aim of this thesis is to increase the understanding of the etiology of 
Parkinson’s disease and the causes of comorbidity of parkinsonism and dementia. 
 
Specific aims of each study: 
 
I. To study the validity of register-based Parkinson’s disease diagnoses in the 
Swedish National Patient and Cause of Death Registers with the aim to find 
the most optimal register-based case definition for use in epidemiological 
studies. 
 
II. To explore the association between Parkinson’s disease risk and 
occupational exposure to metal dust, wood dust, animal handling, 
pesticides, stone and concrete dust, inorganic dust, chrome and nickel 
dust, quartz dust, organic dust, welding smoke, oil, asbestos, organic 
solvents and irritating gas. 
 
Papers III, IV and IVtw are studies of the familial coaggregation of Parkinson’s disease 
and dementia that aimed to elucidate whether there is shared familial risk for 
parkinsonism and dementia, which could be one of the mechanisms explaining 
comorbidity of the disorders. 
 
The specific aims of each study were: 
 
III. To systematically review and synthesize published studies on familial 
coaggregation of Parkinson’s disease and dementia. 
 
IV. To investigate familial coaggregation of Parkinson’s disease and dementia 
in first-degree relatives. To investigate familial aggregation of Parkinson’s 
disease, parkinsonian disorders, Alzheimer’s disease and dementia in first-
degree relatives. 
 
In addition, results are presented from a study where the aim was to 
investigate familial aggregation and coaggregation of Parkinson’s disease 
and dementia in monozygotic and dizygotic twins. This study will be 
referred to as Study IVtw in order to distinguish it from Study IV. 
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4 DATA 
4.1 REGISTER-BASED DATA 
In this thesis, register-based epidemiology and register-based studies refer to 
epidemiological studies that use data from registers at any point in the research 
process. In Sweden, that definition most likely includes the vast majority of 
epidemiological research, including studies where the researchers themselves do not 
consider the study to be register-based.  
What is meant by “register”? Usually it refers to administrative registers; that is, 
depositories of data for some kind of unit (persons, regions, businesses, etc.) collected 
for administrative purposes (including economic or statistical evaluations). These data 
may be public, meaning that anyone has the right to access them, such as personal tax 
records in Sweden, or they may be protected, such as hospital discharge records. But 
the key is that the data are collected primarily for non-research purposes. This type of 
data is also called “secondary data” or “non-primary data”. For example, when 
Swedes apply to university, it’s not necessary to state grades from upper secondary 
school on the university application as all grades are deposited into a central register 
and then retrieved automatically when the application is processed. Consequently, 
there is a register of educational achievement available to researchers. However, 
“register” can also refer to a depository of data collected for research purposes, but 
not for the purpose of one particular study. For example, the STR collects various data 
on twins, or the so called national quality registers for health and medical services 
which collect data for monitoring purposes, but also for research. Register-based 
studies can be divided into three general categories, although these are not mutually 
exclusive; 
1. Registers used as sampling frame for primary data collection 
E.g., a case-control study may use the National Patient Register (NPR) to 
identify cases and the Total Population Register (TPR) to sample controls. After 
sampling, the cases and controls are contacted by the researchers and primary 
data is collected. 
2. Registers used for follow-up or for additional data to primary data collection 
E.g., participants of a study may be recruited in the community through ads or 
personal contacts and then after primary data collection, register-based data 
may be added through record linkage (study I, II, IVtw). 
3. Exclusively data from registers used without primary data collection 
E.g., several registers are linked together in a relational database and the 
entire study is conducted on the register-based data without ever contacting 
the participants or collecting any primary research data (study IV). 
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4.1.1 Personal identification numbers 
In 1947 Sweden established personal records administered by the local parishes for all 
residents.61 On the personal record, which stated information such as date and place 
of birth, sex and address, a personal identification number was assigned. For children 
aged 15 or younger (i.e. born 1932 or later), names and personal identification 
numbers of living parents were also recorded (this enabled the multigeneration 
register (MGR) to be established in the 2000’s). The personal identification number 
consists of a six-digit birth date and a four-digit identification number which indicates 
sex (if the digit in the third position is even (female) or odd (male)) and the county of 
first residence for persons born until 1990.62 The last digit of the four-digit 
identification number is a check digit derived from the 9 other digits and its calculation 
is based on the modulus 10-method. 
Immigrants to Sweden are assigned a personal identification number if they become 
permanent residents or intend to stay for more than one year. In special 
circumstances immigrants may receive a personal identification number that has been 
previously assigned to a deceased person. This is most likely to happen if date of birth 
is uncertain in which case January 1st or July 1st is most often chosen, leading to a 
shortage of unique personal numbers for these birthdates in certain years. At present 
about 15,000 personal identification numbers have been reused.62 A list of reused 
numbers is kept by Statistics Sweden and data linked to these numbers is usually 
deleted in population-based register studies to avoid problems related to data from 
two persons being linked to the same observation. 
The personal identification numbers are the basis for all public administration in 
Sweden and thus all administrative (and other) registers are indexed by this number. 
This enables registers to be linked to each other and to primary research data. 
 
4.1.2 National Patient Register 
Sweden has universal health insurance covering all residents. Patients pay minor out-
of-pocket fees for health care visits and hospital stays, but the majority of the cost is 
carried by the public insurance system which is financed by taxes levied by counties 
via each resident’s home municipality. Although the National Board of Health and 
Welfare provides national guidelines and policy, health care in Sweden is 
decentralized; each of the presently 21 counties has wide-ranging autonomy with 
regards to health care organization and public health policy.  
In 1964 an administrative register of hospital discharge records was established at the 
National Board of Health and Welfare (then Medicinalstyrelsen), the NPR.63,64 
Reported data include personal identification numbers, dates of admission and 
discharge, type of hospital department, whether the hospital stay was scheduled or 
not (i.e. an emergency), and most importantly, cause of hospitalization 
operationalized as a primary diagnosis and contributory diagnoses coded according to 
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the current version at time of discharge of the Swedish translation of the International 
Classification of Diseases (ICD) as determined by the World Health Organization.65 This 
data is entered more of less raw into the NPR, meaning that excerpts available to 
researchers frequently include spelling mistakes, date irregularities and missing 
variables. 
At first, 6 counties in and around the Uppsala area in Sweden were included in the 
NPR.64 Between 1964 and 1983, there was a gradual expansion of number of included 
counties until the register covered about 85% off all discharges. In 1984 it was decided 
that the register should cover all counties, but plans to expand the register were 
halted due to concerns about personal integrity and security of the data from the Data 
Inspection Board. Until the legal and ethical issues could be resolved, hospital 
discharge data continued to be collected without personal identification numbers. 
When the legality of the register was finally settled in 1993, most counties were able 
to retroactively update the register with personal identification numbers, but for 
some regions of Sweden data from the beginning of the period (1984-1986) was lost. 
Thus, the register has complete national coverage only from January 1st 1987. In 2001 
the next major change of the NPR occurred when outpatient visits from hospital-
based clinics began to be reported as well. These data are integrated into the NPR, but 
are sometimes referred to separately as data from the Outpatient Register (OPR). 
Primary care data is not included in NPR. 
 
4.1.3 Cause of Death Register 
There has been a legal framework to report deaths along with the causes of death in 
Sweden in various forms since at least 1749.66 The history of the organization of 
Swedish death data reporting is fascinating, but unfortunately not within the scope of 
this thesis. The Cause of Death Register (CDR),67 in the form available for 
epidemiological research, includes deaths for all Swedish residents, regardless of 
whether they died in Sweden or abroad, and it is complete since January 1st 1961 
(there is also some data digitized for the period 1952-1960). While the NPR contains 
raw data and diagnoses coded according the Swedish versions of the ICD, the CDR is 
cleaned and causes of death are coded according to the international versions of ICD. 
For researchers who use both registers, the difference in data quality is tangible 
between NPR and CDR with regards to completeness, spelling mistakes and date 
errors. The most important variable for the administrative cause of death statistics is 
the underlying cause of death, defined as the disease or injury that initiated the chain 
of events that led to death, or the circumstances of the accident or violent act that led 
to death. The underlying and contributing causes of death are assigned by a physician 
who may use autopsy data, hospital or primary care records, reports from family 
members or a visual inspection of the body as basis for the determination. The CDR 
does contain a variable indicating if an autopsy was performed, but it’s not indicated if 
neuropathological data was collected at autopsy. 
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4.1.4 Multigeneration register 
Information on parents and children from the personal records for Swedish residents 
that have existed in different forms since 1947, the Population and Housing censuses 
1960-1990 and the TPR were developed into the MGR by Statistics Sweden during 
2000-2005 and is since then continuously updated.61 The core of the register contains 
5 variables: Index person’s personal identification number and the personal 
identification numbers of their biological mother, biological father, adopted mother 
and adopted father. If one of the parents is unknown or does not have a personal 
identification number or if the index person was not adopted, the concerned variable 
is left blank. 
Included index persons are those born in Sweden since 1932 who were residents at 
any point since 1961. Linkage between index persons and parents is possible if the 
parents were alive and residents in 1947 or after. Immigrated index persons are linked 
to parents if they immigrated with their parents before age 18. Thus, even if full 
siblings immigrated together, they can only be identified as siblings in the MGR if both 
immigrated before age 18 together with their parents. Paternity is established for men 
married to the biological mother at time of birth or by acknowledgement. 
 
4.1.4.1 Studies of familial aggregation and coaggregation in MGR 
Table 4.1. shows a fictional excerpt of three observations from the MGR. This data can 
be restructured in many different ways to be used in familial aggregation and 
coaggregation analyses, for instance in the form of relative dyads; relative pairs with 
informative order (each pair gives rise to two dyads). Table 4.2 lists all possible relative 
dyads that can be found in the data from table 4.1., with first-degree relative dyads 
marked by a star. In this example, the information of three index persons constructed 
26 relative dyads, of which 12 were for first-degree relatives. In its basic form, the 
MGR does not contain data on sex and birthdates, but if we were to merge on data 
from TPR we can further classify two dyads, Luke-Leia and Leia-Luka as DZ opposite 
sexed twins. 
 
Table 4.1. Fictional excerpt from the multigeneration register. For illustration purposes the 
names of included persons are listed, normally excerpts used by researchers would only 
contain coded index numbers. 
Index person Biological mother 
Biological 
father 
Adopted 
mother 
Adopted 
father 
Anakin  Shmi     
Luke  Padme  Anakin  Beru  Owen  
Leia  Padme  Anakin  Breha Bail  
Ref: http://starwars.wikia.com/wiki/Skywalker_family 
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Table 4.2. Fictional example of relative dyads. *indicates first-degree relatives. 
Spouses defined as biological parents of at least one child. 
Index person Relative Relation type 
Anakin Shmi Offspring-parent* 
Anakin Padme Spouse-spouse 
Anakin Luke Parent-offspring* 
Anakin Leia Parent-offspring* 
   
Shmi Anakin Parent-offspring* 
Shmi Luke Grandparent-grandchild 
Shmi Leia Grandparent-grandchild 
   
Padme Anakin Spouse-spouse 
Padme Luke Parent-offspring* 
Padme Leia Parent-offspring* 
   
Luke Anakin Offspring-parent* 
Luke Padme Offspring-parent* 
Luke Shmi Grandchild-grandparent 
Luke Leia Full sibling-full sibling (DZ twin-DZ twin)* 
Luke Beru Adopted child-adopted parent 
Luke Owen Adopted child-adopted parent 
   
Leia Anakin Offspring-parent* 
Leia Padme Offspring-parent* 
Leia Shmi Grandchild-grandparent 
Leia Luke Full sibling-full sibling (DZ twin-DZ twin)* 
Leia Breha Adopted child-adopted parent 
Leia Bail Adopted child-adopted parent 
   
Beru Luke Adopted parent-adopted child 
   
Owen Luke Adopted parent-adopted child 
   
Breha Leia Adopted parent-adopted child 
   
Bail Leia Adopted parent-adopted child 
 
Using the data in table 4.2 with additional linked data on disease outcomes, we can 
design several types of familial aggregation studies: 
• Cohort of dyads 
The most efficient way to use the data is to create a cohort of dyads where 
each observation is a study person (who experiences the outcome) and they 
are linked to only one relative at a time (who provides the exposure). In this 
design we can chose whether the exposure should be latent, meaning that we 
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disregard at what date or age the relative potentially becomes affected by the 
exposing disease and just treat it as an ever/never exposure, or time-varying, 
meaning that if the relative becomes affected during the follow-up period, the 
study person’s observation is split into two observations: one for the 
unexposed time and one for the exposed time. However, there are also 
drawbacks to using a cohort of dyads. Firstly, as table 4.2 illustrates, the data 
from even relatively small excerpts of the MGR grows exponentially when 
dyads are extracted. When a whole population cohort from the MGR is used, 
there can easily be 10 million or more dyads included and that may be 
unmanageable to analyze without very powerful computers, especially if it’s 
survival type data with delayed entry. The problem of dependency in data is 
very important to handle in cohorts of dyads because not only is there family-
level clustering, but also individual-level clustering. Lastly, for communication 
reasons, a cohort of dyads is not very intuitive as each person has potentially 
multiple observations and the number of observations is proportional to the 
number of relatives that person has. For instance, if an outcome is associated 
with family size an incidence rate or prevalence estimate from a cohort of 
dyads does not have the same interpretation as that estimate from a cohort of 
individuals. 
• Cohort of individuals 
If we collapse all dyads for a unique individual and instead consider the 
relatives as a group we can construct a cohort study such as the one described 
in paragraph 2.3.1 (study IV, IVtw). The advantage is that the complexity and 
data volume is reduced and, since it’s a cohort of actual persons and not 
dyads, descriptive statistics will now be directly interpretable in relation to the 
underlying population. There are also no repeated observations for the same 
individual, but there is still family-level clustering which means that standard 
errors still need to be adjusted in analyses.  
• Matched case-control/matched cohort study 
An alternative way to reduce the data volume and complexity of a cohort of 
dyads but still retain as much information as possible is to use the dyads as a 
sampling frame where case dyads are matched to control dyads (or compared 
to control dyads otherwise sampled). Controls dyads are thus matched on 
characteristics of both the index person and the relative, not just the index 
person. If a density matching method is used, potentially both time-lines can 
be “matched away”, although this is challenging and thus usually only one of 
the time-lines is used. Since matching is done on both the case (who 
experiences the outcome) and the exposing relative, the resulting dataset has 
characteristics of both a case-control dataset and matched cohort dataset and 
can potentially be analyzed both ways. 
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4.2 THE SWEDISH TWIN REGISTRY 
STR includes twins born in Sweden since 1886, at present more than 95,000 twin 
pairs.68-71 The majority of the twins have at some point contributed questionnaire data 
and, increasingly, biological data, to the register. In addition to large volumes of data 
collected by the STR, the overall register and sub-cohorts of the register are routinely 
linked to Swedish population-based administrative registers. 
 
4.2.1 Questionnaire data 
STR was initiated in the 1950’s with the original aim to study adverse health effects of 
smoking.69 At that time birth records in Sweden were administered by parishes and so 
every parish was contacted and asked to provide contact information on same-sexed 
twins born between 1886 and 1925. Beginning in 1961 all identified same-sexed twin 
pairs were sent questionnaires and a register was established that included 
information on all twin pairs were both twins agreed to be included by responding to 
the questionnaire. This cohort is now known as the “old cohort” of the STR. In 1973 a 
second cohort consisting of same-sexed twins born 1926-1958, the “middle cohort”, 
was established in a similar way with mailed questionnaires. Collected data included 
medical history, occupational information, lifestyle habits and demographic data. 
 
4.2.2 Zygosity determination 
Zygosity of same-sexed twins was determined using the question: “During childhood, 
were you and your twin partner as like as ‘two peas in a pod’ (lika som bär) or not 
more like than siblings in general?” in the questionnaires. If both twins in a pair replied 
that they were alike, the pair was classified as MZ. For same-sexed twin pairs from the 
old and middle cohorts whose zygosity was undetermined after the initial 
questionnaires and who participated in SALT (see below), this additional question was 
asked: “How often did strangers have difficulty in distinguishing between you and 
your twin partner when you were children?”. If both twins replied that they were 
often mixed up by strangers, they were classified as MZ. This method of determining 
zygosity has been shown to have a validity of 99% when compared to determination 
based on genotyping.68  
 
4.2.3 Screening Across the Lifespan of Twins Study 
Screening Across the Lifespan of Twins Study (SALT)68,69 was an endeavor between 
1998 and 2002 to screen all twins born before 1958 (i.e. the old and middle cohorts) 
for various health outcomes. Opposite sexed twins who were not originally included in 
the middle cohort were also screened. Twins were first contacted with a letter and 
then through a computer assisted telephone interview. The battery of questions 
included common complex diseases, health behavior, medications, lifestyle factors, 
occupation and much more.  
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4.2.4 SALT/PARKIN 
All twins who were 50 years or older at their screening interview in SALT were (or 
their proxy was) screened specifically for PD.72 Besides being asked directly about 
whether they had a PD diagnosis there were also questions pertaining to the presence 
of bradykinesia and tremor, such as presence of small handwriting, poor balance, feet 
“getting stuck to the floor”, shaking arms or legs, difficulty buttoning buttons, shuffling 
feet or taking tiny steps when walking, soft voice and slow movements.72 
Furthermore, questions were also asked about the use of PD medication. This 
screening procedure has been validated and shown to be highly sensitive.73 The 
screening interview was the first of three phases of the study which will here be 
referred to as SALT/PARKIN. The second and third phases were a follow-up telephone 
interview of suspected cases and subsequent clinical workup taking place in 2002–
2004. The purpose of the second screening was to exclude from further follow-up 
those with suspected PD who reported symptoms due to diseases other than PD. The 
second screening interview was conducted by telephone by research nurses and 
included additional questions about parkinsonian symptoms and diagnosis, other 
diseases and medications. If the twins remained suspects after the second screening, 
they were invited to a clinical workup or, if they had self-reported PD, were worked up 
by medical record review.  
A parallel study to PARKIN used a similar protocol that included a screening phase and 
a clinical phase to diagnose dementia and Alzheimer’s disease (HARMONY).74 
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5 METHODS 
 
5.1 THE VALIDATION STUDY (STUDY I) 
5.1.1 In brief 
Parkinson’s disease and overall parkinsonian disorder case ascertainment using the 
inpatient data of the National Patient Register and the Cause of Death Register was 
validated against cross-sectional screening and clinical data from the Swedish Twin 
Register (The SALT/PARKIN study). All twins who had participated in the screening 
and/or clinical work-ups were eligible to be included in the study population as gold 
standard positive (n=194) or negative cases (n=35,594). Validity of the register-based 
case ascertainment was measured by the proportion of register-based positive cases 
that were confirmed by the gold standard (the positive predictive value) and by the 
proportion of gold standard positive cases detected by the registers (the sensitivity).  
 
5.1.2 Study population 
The study population included all twins with known PD or non-PD parkinsonian 
disorder status after participation SALT/PARKIN (fig. 5.1). N=132 PD cases and n=62 
cases of other parkinsonism were confirmed. These n=194 persons constituted the 
gold standard positive cases, whereas all who screened negative for PD symptoms or 
were determined to be parkinsonian disorder-free in the clinical work-up were the 
gold standard negative cases (n=35,594). The final study population included 35,788 
twins with available data. 
 
5.1.3 Gold standard 
Twins who self-reported a PD diagnosis in the screening were worked up by review of 
medical records and telephone interview (n=195). Twins who did not report a PD 
diagnosis but who were suspected cases based on their responses to the screening 
questions about symptoms or medications were worked up with a clinical examination 
in their home, an in-person interview and a review of their medical records (n=225). 
The Unified Parkinson’s Disease Rating Scale (UPDRS)75 was used to evaluate 
parkinsonian signs and symptoms. Diagnoses of PD were assigned according to the 
National Institute of Neurological Disorders and Stroke (NINDS)4 criteria by a study 
physician together with movement disorder specialists, who independently assigned 
diagnoses, reviewed cases where there was disagreement and agreed upon final 
consensus diagnoses. Diagnoses of MSA76 (n=3), PSP10 (n=6), LBD42 (n=11) and CvP77 
(n=32) were based on previously published criteria and clinical experience and, where 
available, computer tomography imaging, in line with clinical practice at that time. In 
addition, non-PD parkinsonian cases were diagnosed with parkinsonism in dementia 
(n=5) and parkinsonism of unknown cause (n=5).  
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Of all parkinsonian disorder cases, 107 (55.2%) were men. The mean (Standard 
deviation, SD) age at screening was 63.1 (9.7) years for the study population overall 
and 74.7 (8.8) years for the parkinsonian disorder cases. Mean (SD) age at onset was 
68.7 (11.1) years, and mean (SD) disease duration at screening was 6.3 (6.6) years.  
 
Fig. 5.1. Flow chart depicting the gold standard cohort included in the validation 
study (Study I). See Wirdefeldt et al.72 for a more detailed flow-chart of the PARKIN 
study. a) N=53 twins were screened for PD in HARMONY and therefore had not been 
included in the original eligible sample, b) Twins were excluded if lost to follow-up for 
instance due to refusal to participate in the 2nd screening, c) N=14 twins were non-
participants in the screening but still included in the clinical work-up as cotwins. The 
final cohort with gold standard diagnostic status included n=35,788 participants. PD: 
Parkinson’s disease. 
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5.1.4 Validation procedure 
ICD codes used to identify parkinsonian disorders in study I as well as in studies II, IV 
and IVtw are listed in table 5.1. To identify cases of parkinsonian disorders in the NPR 
(inopatient data only) and CDR, we used comprehensive definitions that included all 
primary and contributory diagnoses in the NPR and all underlying and contributory 
causes of death in the CDR. To determine the most optimal register-based PD case 
definition we explored different ways of restricting the definition of PD in the 
registers, as follows:  
1. By excluding register cases who, at any point, had had a non-PD parkinsonian 
disorder diagnosis (e.g. CvP) in the NPR in addition to a PD diagnosis. 
2. By using primary diagnoses only in the NPR or underlying causes of death only 
in the CDR.  
3. By using diagnoses (primary or contributory) from neurological, neurosurgical 
and geriatric departments only in the NPR. 
Table 5.1. International Classification of Diseases (ICD) codes used in Studies I, II, IV, IVtw. PD codes in 
bold. CvP: Cerebrovascular parkinsonism, PD: Parkinson’s disease, PSP: Progressive supranuclear palsy. 
ICD-code Diagnosis 
Used in Study 
I II IV/IVtw 
1967 (ICD-7) 
350 Paralysis agitans (PD) X X X 
1968-1986 (ICD-8) 
342.00 PD X X X 
342.08 Other defined parkinsonism X X X 
342.09 Unspecified parkinsonism X X X 
1987-1996 (ICD-9) 
332.0 PD X X X 
332.1 Secondary Parkinsonism  X  
333.0 Other degenerative diseases of the basal ganglia X X X 
1997 (ICD-10) 
F02.3 Dementia in Parkinson's disease   X 
G20 PD X X X 
G21.0 Malignant neuroleptic syndrome  X  
G21.1 Other drug-induced secondary parkinsonism  X  
G21.2 Secondary parkinsonism due to other external agent  X  
G21.3 Postencephalitic parkinsonism  X  
G21.4 Vascular parkinsonism (i.e. CvP) X X X 
G21.8 Other defined secondary parkinsonism X X X 
G21.9 Unspecified secondary parkinsonism X X X 
G23.1 Progressive supranuclear ophthalmoplegia (i.e. PSP) X X X 
G23.2 Striatonigral degeneration X X X 
G23.9 Unspecified degenerative disease of basal ganglia X X X 
G25.9 Unspecified extrapyramidal and movement disorder X X X 
G31.8A Lewy body disease   X 
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Validation measures are summarized in fig. 5.2. We were primarily interested in 
validating register-based case ascertainment in terms of Positive predictive value 
(PPV) and sensitivity. All validity measures were calculated for two outcomes:  
1. Any parkinsonian disorder 
True positive cases of any parkinsonian disorder did not have to have had the 
same parkinsonian disorder in the registers and the gold standard, e.g. a gold 
standard CvP case given a PD diagnosis in the registers would still be true 
positive. 
2. PD  
True positive cases had to have a PD diagnosis in the registers and the gold 
standard. 
Clopper-Pearson exact confidence limits for proportions78 were used to construct 95% 
CI for the validity estimates. Even if cell counts are low and the proportion is close to 0 
or 1, these confidence intervals do not cross 0 or 1 which is otherwise a risk with the 
standard way of calculating CI for proportions. 
 
5.1.4.1 Positive predictive value 
The PPV was calculated as the proportion (expressed as a percentage) of true positive 
cases among all register-based positive cases (true positive plus false positive). As the 
index date for each participant (the date at which their gold standard positive or 
negative diagnosis status was known), we used the date of initial telephone contact in 
the SALT screening. For the NPR, all persons in the study population who had been 
diagnosed with a parkinsonian disorder or PD between the start of follow-up in NPR 
(1964) and their index date, the PPV represented the proportion whose diagnosis was 
confirmed by the gold standard. For the CDR, all persons who died within three years 
of their index date and had a parkinsonian disorder or PD diagnosis listed as a cause of 
death, the PPV represented the proportion who had also been given a positive 
diagnosis by the gold standard. 
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5.1.4.2 Sensitivity 
Sensitivity was calculated as the proportion (expressed as a percentage) of true 
positive cases among all gold standard positive cases (true positive plus false 
negative). For the NPR, sensitivity represented the proportion of gold standard 
parkinsonian disorder or PD cases who at any point between 1964 and end of follow-
up in 2009 received a register-based diagnosis. For the CDR, sensitivity represented 
the proportion of all gold standard positive cases who died between their index date 
and end of follow-up in 2008 and who had a diagnosis listed as a cause of death.  
  
Fig. 5.2. Validity measures. FN: False negative, FP: False postitive, NPV: Negative 
predictive value, PPV: Positive predictive value, TN: True negative, TP: true positive. 
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5.2 THE OCCUPATIONAL EXPOSURE STUDY (STUDY II) 
5.2.1 In brief 
The association between Parkinson’s disease or any parkinsonian disorder and 14 
occupational risk factors was investigated in a population-based prospective cohort 
design. Occupational data for Swedish male twins (n=14,169) from questionnaires in 
1967 or 1973 was linked to a job exposure matrix to enable grouping of occupations 
according to level of probability of exposure to 14 occupational exposures. The study 
population was followed in the National Patient and Cause of Death Registers for 
incident Parkinson’s disease and other parkinsonian disorders from baseline 
occupational data collection until end of 2009 (up to 43 years). We identified 234 
parkinsonian disorder cases including 204 Parkinson’s disease cases. Hazard ratios 
with 95% confidence intervals adjusted for age, smoking and educational status at 
baseline were used to estimate the relative risk of disease associated with 
occupational exposure. 
 
5.2.2 Participants 
The study population is illustrated in the flow chart in fig. 5.3.  All twins in the old 
(born 1886-1925) and middle (born 1926-1958) cohorts of the STR were eligible to be 
included. However, due to high levels of missingness on occupational information 
among women it was decided to include only men. Excluded were also those who 
were younger than 25 at baseline in the middle cohort (effectively truncating the birth 
cohort in 1947), those who died before January 1st 1967 in the old cohort and those 
lost to follow-up from the STR. The final study population included 20,225 men of 
which 14,167 (70.0%) had complete data on exposure and covariates and could be 
included in the main analyses. Mean age at baseline in the study population was 44.0 
(SD 13.0) and mean follow-up time was 29.1 years (SD 11.1). 
 
5.2.3 Outcome 
Incident cases of PD were ascertained by record linkage of the STR with the NPR (only 
inpatient data) and the CDR. In the present study NPR data was available for 1967-
2009 and CDR data was available for 1967-2008 (dates of death for 2009 which was 
not covered by the CDR were taken from the TPR). Cases were defined as any 
parkinsonian disorder if there was a relevant diagnosis in the NPR or CDR (table 5.1). 
Cases were defined as PD if there was a PD diagnosis and no non-PD parkinsonian 
disorder diagnosis in the NPR or CDR. Please note that this register-based definition of 
PD is different from that used in studies IV and IVtw. Date of ascertainment was 
defined as date of first hospital record of a parkinsonian disorder, or, for cases only 
identified through the CDR, date of death.  
We identified 336 incident cases of Parkinsonian disorders, whereof 293 (87.2%) were 
PD cases. Of 294 cases identified in the NPR, 119 cases (40.5%) were also identified in 
the CDR. Forty-two cases (12.5%) were identified in death records only. Of 43 
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parkinsonian disorders cases, 29 (67.4%) had a PD diagnosis, but were classified as 
non-PD parkinsonian disorder due to an additional non-PD parkinsonian disorder 
diagnosis. Mean age of ascertainment of outcome for all cases was 75.5 (SD 8.6) years 
(range 43.4-94.6 years). The overall crude incidence rates per 100,000 PYR were 49.8 
for PD and 57.1 all parkinsonian disorders. 
 
5.2.4 Exposure 
For the old cohort, questions about main occupation in adulthood were included in 
the 1967 questionnaire when the mean age of the twins was 55.1 (SD 9.6, range 41.0-
81.0) years. For the middle cohort, questions about present occupation were included 
in the 1973 questionnaire when the mean age of the twins was 34.7 (SD 6.5, range 
25.0-47.0) years. Among men with occupational data, the crude incidence rate of PD 
per 100,000 PYR was 49.1, whereas among men without occupational data the rate 
was 52.2 per 100,000 PYR. 
Fig. 5.3. Flow chart depicting inclusion of study persons to the occupational 
exposure study (Study II).  
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Occupations were coded according to the 3-digit level of occupational codes used in 
the 1970 census, based on the Nordic Standard Occupational Classification of 1965 
(Nordisk yrkesklassificering), adapted from the International Standard Classification of 
Occupations. A job exposure matrix (JEM) was used to assess exposures for each 
person based on occupation at baseline. The JEM was developed by industrial 
hygienists at Karolinska Institutet for population-based studies of occupational 
exposures in the years 1960-1980,79,80 corresponding to the average working age of 
the men in the study population. The JEM assesses probability of occupational 
exposure to chemical and biological compounds in four classes. Classes 0-3 represent 
increasing probability of specific exposures within families of occupations, from very 
low probability (class 0: less than 1/10 of persons within the occupational family 
exposed), to high probability of exposure (class 3: more than 2/3 exposed). The 
complete JEM contains information for 29 exposures in 248 occupations. Based on a 
cut-off level of at least 5% exposed in the study population, 14 of the 29 occupational 
exposures were selected for analysis.  
Education and smoking were included to control for possible confounding. 
Information was taken from questionnaires in 1961 and 1963 for the old cohort and in 
1973 for the middle cohort. Educational level was categorized as having completed 
compulsory school only or any higher education. In this study population, compulsory 
school was 6, 7 or 8 years of education depending on birth year. Smoking status was 
categorized as never, current, or past smoker at the time of the questionnaire.  
Of 336 cases, 254 (75.6%) had occupational data and 234 (69.6%) had complete data 
on occupation, education and smoking status. 
 
Fig. 5.4. Directed acyclical graph depicting a possible model of the causal pathways 
between occupational exposure and Parkinson’s disease (Study II). PD: Parkinson’s 
disease, U: Unmeasured confounding. 
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5.2.4.1 Causal pathways 
Fig. 5.4 shows a possible model for the causal pathways between PD, occupational 
exposure, education, smoking, age and sex illustrated as a DAG. The hypothesis is that 
occupation causes exposure, which may cause PD and subsequent detection of PD in 
the registers. Smoking is possibly causally (inversely) associated with PD and likely 
associated with occupation, although not causally. It’s more likely that there is a 
common cause of smoking status and occupation, for instance, socio-economic status 
(which may be partially captured by education). Education is associated with PD but 
the mechanism of this association may go through occupation and occupational 
exposure, in which case education would not be a confounder. However, education 
may be associated with the detection of PD, although this is not highly likely due to 
the nature of the public health insurance system in Sweden. We also cannot rule out 
unmeasured residual confounding. Note that sex is controlled for by stratification. 
 
5.2.5 Statistical Methods 
The study population was followed for PD and other parkinsonian disorders from 
baseline collection of occupational data until date of ascertainment of case status, 
December 31st 2009 (end of follow-up), or date of death, whichever came first. 
January 1st 1967 was chosen as baseline date for the old cohort and January 1st 1973 
was chosen for the middle cohort. Theoretical follow-up of the study population is 
Fig. 5.5. Lexis diagram depicting the follow-up in the occupational exposure study 
(Study II).  
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illustrated as a Lexis diagram in fig. 5.5. Incidence rates (IR) of PD were calculated as 
events divided by time-at-risk, reported per 100,000 PYR. The association between 
occupational exposure and PD was modeled using Cox proportional hazard regression 
yielding HRs with 95% CI. Age was used as the underlying time scale. Educational level 
and smoking status were included as covariates in the statistical model. 
 
5.3 THE SYSTEMATIC REVIEW AND META-ANALYSIS (STUDY III) 
5.3.1 In brief 
Familial coaggregation of Parkinson’s disease and dementia was investigated by 
conducting a systematic review and meta-analysis. PubMed was searched for studies 
published through end of October 2012 on dementia risk associated with family 
history of Parkinson’s disease (or parkinsonism), or Parkinson’s disease risk associated 
with family history of dementia. Three independent investigators screened 
publications, extracted data and assigned a quality score based on four indicators to 
each included study. Hazard ratios or odds ratios from included studies were 
summarized into meta-estimates using random effects models and illustrated in forest 
and funnel plots. Heterogeneity and publication bias were tested using the Higgins’ 
and Egger’s tests, respectively. Of 405 studies found in the initial search, 12 met the 
inclusion criteria with and an additional 4 studies identified through references and 
referrals, a total of 16 studies were reviewed, with 14 included in any meta-analysis. 
 
5.3.2 Inclusion of studies 
We followed the Meta-Analysis Of Observational Studies in Epidemiology (MOOSE)81 
reporting guidelines which are listed in table 5.2.  
 
Table 5.2. Meta-Analysis Of Observational Studies in Epidemiology (MOOSE)81 reporting 
guidelines. 
Reporting of background should include 
Problem definition 
Hypothesis statement 
Description of study outcome(s) 
Type of exposure or intervention used 
Type of study designs used 
Study population 
Reporting of search strategy should include 
Qualifications of searchers  
Search strategy, including time period included in the synthesis and keywords 
Effort to include all available studies, including contact with authors 
Databases and registries searched 
Search software used, name and version, including special features used  
Use of hand searching  
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Table 5.2 cont. 
List of citations located and those excluded, including justification 
Method of addressing articles published in languages other than English 
Method of handling abstracts and unpublished studies 
Description of any contact with authors 
Reporting of methods should include 
Description of relevance or appropriateness of studies assembled for assessing the 
hypothesis to be tested 
Rationale for the selection and coding of data 
Documentation of how data were classified and coded 
Assessment of confounding 
Assessment of study quality, including blinding of quality assessors; stratification or 
regression on possible predictors of study results 
Assessment of heterogeneity 
Description of statistical methods in sufficient detail to be replicated 
Provision of appropriate tables and graphics 
Reporting of results should include 
Graphic summarizing individual study estimates and overall estimate 
Table giving descriptive information for each study included 
Results of sensitivity testing 
Indication of statistical uncertainty of findings 
Reporting of discussion should include 
Quantitative assessment of bias 
Justification for exclusion 
Assessment of quality of included studies 
Reporting of conclusions should include 
Consideration of alternative explanations for observed results 
Generalization of the conclusions 
Guidelines for future research 
Disclosure of funding source 
 
To identify the participating studies we searched (PubMed) using the following search 
string: 
((parkinson*) AND (dement* OR alzheimer*)) AND (risk OR epidemiolog*) AND 
((famil* AND (risk OR histor* OR aggreg*)) OR parent* OR sibling* OR twin* OR 
relative*) 
The search was performed on October 30th, 2012 and thus all studies published until 
that date were eligible to be included. Fig. 5.6 illustrates the inclusion of studies to the 
qualitative and quantitative review. The initial search returned 405 results, which 
were exported as  
1. A list of titles into a spreadsheet  
2. A list of abstracts into a word document  
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These two documents were screened independently by two investigators in three 
phases:  
1. All titles (n=405) were read to exclude studies which did not appear to fulfill 
the eligibility criteria (see below). 
2. The abstracts of the eligible studies (n=277) were read to exclude studies 
which did not appear to fulfill the inclusion criteria (see below). 
3. The full text of the remaining studies (n=39) was read to ascertain if they 
fulfilled criteria for inclusion (n=12 with n=4 additional studies identified 
through references and referrals, totaling n=16 included studies). 
Of the 27 studies from the search which were found not to fulfill the inclusion criteria 
in the last phase, 14 studies were on familial coaggregation between AD and/or PD 
with another outcome (such as amyotrophic lateral sclerosis (ALS), PDD, LBD, PSP or 
depression), 3 studies solely concerned the ALS-PD complex of Guam and 10 studies 
did not include a control group or were missing other crucial data. 
Two studies fulfilled the criteria to be included in the systematic review, but were 
excluded from the meta-analysis; one due to not including enough relevant 
quantitative data82 and one due to unclear results.83 The latter study included 
Standardized incidence ratios (SIR) for AD risk associated with having a sibling with PD 
and SIRs for PD risk associated with having a sibling with AD, but it was unclear from 
the published article which estimate was for which comparison. We were in contact 
with the authors of the study but did not receive sufficient information to include it. 
Ultimately, the meta-analyses included estimates from 14 studies. 
 
5.3.2.1 Eligibility criteria 
We considered published observational epidemiological studies that met the following 
criteria: 
1. Study design was case-control, cohort, reconstructed cohort or cross-sectional 
2. Outcome was disease status (incident or prevalent) of PD, parkinsonism, AD or 
dementia 
3. Exposure was family history of the opposite disease defined as ever/never 
disease status among one or any first-degree relative (e.g. if exposure was 
family history of PD, outcome was AD, or vice versa) 
Note: We considered studies which included only one type of first-degree 
relatives to be eligible but in practice all studies included in the meta-analyses 
assessed family history in both siblings and parents/offspring. Only one study83 
had used only siblings but this study had to be excluded from the meta-
analysis for other reasons and was only reviewed qualitatively (as discussed 
above). 
4. To be included in the quantitative analysis (meta-analyses) the studies also had 
to include a crude or adjusted effect estimate of association, such as an OR, 
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HR/incidence rate ratio (IRR) or SIR, with a standard error (SE) or 95% CI, or 
enough data allowing a crude effect estimate to be calculated, such as the 
number of exposed and unexposed among cases and controls in a case-control 
study. 
Following initial independent assessment, the investigators disagreed on the inclusion 
of two studies.84,85 After careful reexamination of the texts of both studies by both 
investigators it was decided by consensus decision to include one85 of the studies and 
exclude the other.84 
Relevant data on study design and results was extracted from all included studies 
(n=16) independently by two investigators. Data on four variables (see below) were 
combined into a quality score. After extraction results were compared and discussed 
and a consensus decision was made for each extracted data point and quality score. 
 
Fig. 5.6. Flow chart depicting the inclusion of studies to the systematic review and 
meta-analysis (Study III).  
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5.3.2.2 Quality score 
We assigned a methodological quality score to all included studies based on four study 
characteristics. For each characteristic the study was given a score of 1 for more 
rigorous method, or 0 for less rigorous method. The scores were summed to give a 
total score ranging from 0 to 4. The quality characteristics were: 
1. Setting: If the study participants could be considered to be sampled in a 
reasonably population-based manner (1) or not (0). For example, using 
neighborhood controls was considered to be a reasonably population-based 
method, whereas spouse controls, hospital-based controls or only hospital-
based cases with an unspecified catchment area was not. 
2. Diagnostic ascertainment in first-degree relatives: If disease status of first-
degree relatives was ascertained by family history interviews only (0) or if 
confirmation by clinical exam or medical record review was sought in some or 
all instances (1). 
3. Study design: If the study was a case-control study that did not enumerate 
first-degree relatives (0) or a cohort or reconstructed cohort study that did 
enumerate first-degree relatives (1). 
4. Inclusion criteria: If the study excluded (0) or included (1) index cases with co-
occurring dementia and parkinsonism, such as in PDD. (See paragraph 5.4.4.1. 
for a causal inference explanation of why this criterion was included in the 
quality score.) 
 
5.3.3 Statistical analysis 
Study specific OR or HR estimates were pooled meta-estimates using the random 
effects model of DerSimonian and Laird and reported with 95% CI.86 In a fixed effects 
model the assumption is that all differences between included estimates in the meta-
analysis are due to sampling variation and not due to variation in the underlying 
population that each sample is drawn from. A random effects model allows variation 
not just in sampling but also in the underlying populations. Thus, we chose to use a 
random effects model because it necessitates fewer assumptions. We did not pool 
ORs and HRs in the same meta-analysis as some meta-analyses have done before.17 
For studies that reported subgroup specific estimates but no overall estimate, we 
collapsed the subgroup estimates before entering them into the meta-analysis. This 
primarily concerned two studies: 
1. Marder et al.52 
This was a reconstructed cohort study which reported relevant HR estimates 
for the association between risk of AD and family history of PD for two groups: 
I. First-degree relatives of PD cases without dementia vs. first-degree 
relatives of matched controls 
II. First-degree relatives of PD cases with dementia vs. first-degree 
relatives of matched controls 
   53 
These two estimates were collapsed before being entered into the meta-
analysis with all other reconstructed cohort studies of dementia risk associated 
with family history of PD (overall for all first-degree relatives and for the meta-
analyses among parent-offspring or siblings only). 
2. Rosen et al.49 
This was a case-control study which reported relevant OR estimates for three 
groups: 
I. AD cases without parkinsonism vs. controls where the exposure was 
family history of PD 
II. PD cases without dementia vs. controls where the exposure was family 
history of AD 
III. Cases referred to as AD/PD cases (i.e. those with both dementia and 
parkinsonism including LBD cases, PD cases and cases of AD with 
extrapyramidal symptoms) vs. controls where the exposure was either 
family history of PD or family history of AD 
The estimates for the association between family history of PD for AD cases vs. 
controls and for AD/PD cases vs. controls were collapsed before being entered 
into the meta-analysis with all other case-control studies of dementia risk 
associated with family history of PD. 
The estimates for the association between family history of AD for PD cases vs. 
controls and for AD/PD cases vs. controls were collapsed before being entered 
into the meta-analysis with all other case-control studies of PD risk associated 
with family history of AD or dementia. 
Where possible, we calculated pooled estimates for some specific subgroups, such as 
sibling relationships and parent-offspring relationships. Heterogeneity among studies 
was evaluated with the Q-statistic from the inverse-variance fixed-effect model and 
with the Higgins’ test yielding the I2 measure.87 Heterogeneity can be said to be a test 
of whether it is likely that the included studies in the meta-analysis all estimate the 
same thing. Statistically significant heterogeneity and a high I2 measure (>25% as a 
rule of thumb) implies that the studies may not be comparable and that the meta-
estimate may not be valid. We constructed forest plots and funnel plots for each 
meta-analysis and assessed the presence of publication bias using Egger’s test for 
funnel plot asymmetry.88 In a funnel plot the estimate of each study is plotted against 
its inverse log SE. Ideally, studies with high power and thus low SE aggregate at the 
“tip” of the funnel whereas studies with lower power and thus high SE spread out at 
the “bottom” of the funnel. If the distribution of estimates appears asymmetric, this 
may be an indication of publication bias. 
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5.3.4 Additional studies 
After completing this systematic review and meta-analysis, results became known 
from three additional studies which, if they had been published before October 2012 
had been eligible to be included. These studies are Study IV89  and IVtw of this thesis, 
which are described in detail further on in this chapter, and a study by Boot et al. 
published in 2013.90 This was a case-control study of LBD and AD cases versus 
matched controls, where first-degree family history of PD was one of many 
investigated risk factors for LBD. Estimates (ORs) were reported for the association 
between family history of PD and LBD in LBD cases vs. age and sex matched controls 
(conditional logistic model) and in LBD cases vs. unmatched AD cases (unconditional 
logistic model adjusted for age and sex). There were no estimates reported for LBD 
plus AD cases vs. controls. As crude numbers were given for both case groups and 
controls, a crude OR was calculated for the association between AD or LBD  and family 
history of PD before being entered into the meta-analysis of all case-control studies of 
risk of AD or dementia associated with family history of PD. 
 
5.4 THE FAMILY-BASED STUDY (STUDY IV) 
5.4.1 In brief 
Familial aggregation and coaggregation of Parkinson’s disease and dementia was 
investigated using the multigeneration register. We constructed two cohorts; a first-
degree relative cohort of persons born 1932–1960 (n=2,775,332) and of persons who 
shared a biological child (spouses) born 1890–1960 (n=4,736,006). The parents of the 
first-degree relative cohort and study persons in both cohorts were followed up for 
dementia and parkinsonian disorders between 1969 and 2009 in the National Patient 
and Cause of Death Registers. We modeled the association between incidence of 
disease and having at least one relative (any relative, sibling, parent or spouse) 
affected by the same or opposite disease using Cox proportional hazard regression 
that estimated hazard ratios with 95% confidence intervals adjusted for age, sex and 
number of relatives. 
 
5.4.2 Participants 
The inclusion of study persons to the cohorts is summarized in the flow chart of fig. 
5.7. We used a large database of several linked population-based registers with about 
15,000,000 unique individuals including all Swedish residents 1960-1990 and their 
parents and children if identified in the MGR. In this database we selected study 
persons for two cohorts:  
1. The first-degree relative cohort 
All individuals born 1932-1960 who were index persons in MGR and could be 
linked to at least one sibling or a parent (n=2,775,332). In the cohort, 93.5% 
were linked to both parents, 5.4% were linked to only their mother and 1.1% 
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were linked to only their father. Via parents we could link full siblings and in 
this way we identified 745,143 sibling clusters with on average 3.1 (standard 
deviation (SD) 1.4) siblings per family. The parents of the members of the first-
degree relative cohort consisted of 2,749,772 persons (they were not 
themselves included in the cohort but through them siblings were linked and 
the exposure status in parent-offspring analyses was ascertained). 
2. The spouse cohort 
All individuals born 1890-1960 with at least one identified spouse, that is 
another individual they shared a biological child born between 1932 and 2010 
with (n=4,736,006). Most individuals were linked to one spouse but 6.8% were 
linked to two spouses and 0.8% to more than two spouses. 
Fig. 5.7. Flow chart depicting the inclusion of study persons to the cohorts in the 
family-based study (Study IV).  
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Study persons were eligible to be included in the cohorts if they were alive and 
residing in Sweden during the follow-up period (1969-2009), and additionally if they 
had not died or emigrated before their 40th birthday. In order to be able to assess 
exposure status, the study persons had to have at least one relative who was also alive 
and residing in Sweden during the follow-up period. 
 
5.4.3 Outcomes 
Incident cases of parkinsonian disorders including PD and dementia including AD were 
ascertained using the outpatient and inpatient NPR and the CDR. See table 5.1 for the 
ICD codes used to identify cases. We considered four different incident outcomes 
which were defined like this (when studying a specific outcome, a person was still at 
risk if any of the other outcomes occurred): 
1. Any parkinsonian disorder: Presence of any parkinsonian disorder or PD code 
in the NPR or CDR 
2. PD: Presence of a PD code as a primary diagnosis in NPR or an underlying 
cause of death in CDR 
3. Any dementia: Presence of any dementia or AD code in the NPR or CDR 
4. AD: Presence of an AD code as a primary diagnosis in NPR or an underlying 
cause of death in CDR 
First date of hospital admission or outpatient visit with a relevant diagnosis was used 
as date of ascertainment for cases identified in the NPR whereas date of death was 
used as date of ascertainment for cases identified in the CDR. An individual could be 
classified as both a parkinsonian disorder and dementia case. 
Age-specific incidence rates of all four outcomes in Study IV (first-degree relative 
cohort only) and Study IVtw is illustrated in fig. 5.8. In the first-degree relative and 
spouse cohorts combined we identified 265,620 dementia cases, whereof 92,280 
(34.7%) were AD cases, as well as 64,206 parkinsonian disorder cases, whereof 39,504 
(61.5%) were PD cases. Among the parents of the first-degree relative cohort, 266,583 
(10.4%) had dementia, including 92,659 who had AD and 55,160 (2.2%) had a 
parkinsonian disorder including 31,967 who had PD.  
 
5.4.4 Exposures 
Exposure was dementia, AD, any parkinsonian disorder or PD status (ever or never) in 
first-degrees relatives (siblings and/or parents) or spouses, depending on the model. 
In analyses of familial aggregation within diseases the outcome and exposure were 
the same condition. In analyses of familial coaggregation between diseases, when the 
outcome was, e.g., dementia or AD, then the exposure was any parkinsonian disorder 
or PD (or vice versa). We were primarily interested in familial coaggregation of PD 
with any dementia. 
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Fig. 5.8. Age-specific incidence rates of parkinsonian disorders and dementia in the family-
based study (Study IV) and the twin study (Sudy IVtw). Note the different scales for IR. AD: 
Alzheimer’s disease, IR: Incidence rate,  PD: Parkinson’s disease, PYR: Person-years. 
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5.4.5 Statistical Methods  
The follow-up in both cohorts is illustrated in the Lexis diagram in fig. 5.9. The study 
persons were followed from January 1st 1969, date of immigration or their 40th 
birthday until December 31st 2009, date of emigration, death or first ascertainment of 
incident outcome disease, whichever came first. We chose to left-censor the cohort at 
age 40 to reduce data volume and because there are very few cases of either 
parkinsonian disorders or dementia diagnosed before age 40. IR per 100,000 PYR were 
calculated as number of events divided by total person-time at risk. To quantify the 
association between disease status in relatives and outcome, we estimated HR with 
95% CI using Cox proportional hazard regression with age as the underlying time-
scale. The models were also adjusted for sex and number of informative relatives as a 
continuous measure (i.e., number of first-degree relatives, full siblings, parents or 
spouses). To account for dependencies in the data, we adjusted the standard errors 
using a robust sandwich estimator clustered on family. 
We studied co-occurrence of dementia and parkinsonism by modeling incidence of 
any dementia or AD in persons who were ever vs. never diagnosed with PD 
themselves. It was not possible to study co-occurring dementia in PD in time-varying 
model (PD cases unexposed before they are ascertained with PD) because the time-
lag between onset and detection of both PD and dementia in the registers makes it 
impossible to ascertain which comes first and a large proportion of the comorbid 
cases were first diagnoses with both conditions on the same date. 
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Fig. 5.9. Lexis diagrams illustrating follow-up in the family-based study (Study IV) and 
the twin study (Study IVtw). Note that cohort overlap in study IV. 
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5.4.5.1 Causal pathways 
A DAG illustrating a possible model of the causal pathways in familial aggregation and 
coaggregation of PD and dementia is shown in fig. 5.10. This DAG makes several 
assumptions concerning the association between PD and dementia in individuals: 
1. A direct causal pathway from PD to dementia means that in cases with both 
PD and dementia, such as LBD and PDD, we assume PD is the underlying cause 
of dementia.  
2. Individual (not shared in families) risk factors (C) that are associated causally 
with both PD and dementia. Please note that C encompasses several potential 
risk factors. 
3. Familial risk factors (FPD/Dementia) that are causally associated with both PD and 
dementia. Please note that FPD/Dementia encompasses several potential risk 
factors. 
Please note that the causal pathway between PDR and Dementia through FPD/Dementia is 
not the only open pathway and thus if we observe familial coaggregation of PD and 
dementia, the presence of FPD/Dementia is indicated but not unequivocally proven. We 
could try to close the pathway through PDRFPDPDDementia by, for instance, 
stratifying (excluding cases with both outcomes), but that action could potentially 
open the pathway PDCDementia, which is otherwise closed due to the collider at 
PD. One might also be tempted to exclude relatives with both PD and Dementia, 
Fig. 5.10. Directed acyclical graph of causal pathways in familial 
aggregation and coaggregation of Parkinson’s disease and 
dementia (Study III, IV, IVtw), 
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effectively conditioning on DementiaR, but this action would only open otherwise 
closed causal pathways through FDementia and should be avoided. 
 
5.4.6 The Twin Study (Study IVtw) 
In parallel with the family-based study we also attempted to investigate familial 
aggregation and coaggregation of PD and dementia in MZ and DZ twins from the STR. 
The methods were basically the same as in Study IV with a few differences: 
• We included all twins from the old (born 1886-1925) and middle cohorts (born 
1926-1958). DZ opposite sexed twins born 1926-1958 were also included. The 
complete cohort included 76,763 twins in 36,823 complete pairs, of which 
9,108 were MZ pairs. 
• Follow-up was 1974-2010 for all twins (fig. 5.9). 
• As we had available clinical data on parkinsonian disorders and dementia in 
the STR from the SALT/PARKIN72 and SALT/HARMONY74 studies, we 
supplemented the register-based diagnoses with additional clinical diagnoses. 
For cases only diagnosed clinically, first date of screening contact in SALT was 
used as the date of ascertainment. We identified 1,000 parkinsonian disorder 
cases including 882 PD cases and 4474 dementia cases including 2,893 AD 
cases. 17.3% and 10.9% of respectively the parkinsonian disorder and 
dementia cases were diagnosed clinically (the rest were register-based cases). 
Age-specific incidence rates are shown in fig 5.8. 
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6 ETHICAL CONSIDERATIONS 
It is very important to ensure the personal integrity of research participants, whether 
they consented directly or indirectly to participate in a particular study. When 
research participants are never contacted directly by researchers or are deceased or 
unable to consent, an ethical review board may consent to the use of personal data in 
their place.  This was the situation for studies I, II, IV and IVtw in this thesis and the 
primary ethical issue was data safety to ensure the participants’ integrity.  
As researchers, we do not have access to personal numbers in our register-based data 
and reverse identification is strictly prohibited by law. It has never happened that 
personal data has leaked from a research institution working on registers, but that is 
not a reason to take the risk lightly. If sensitive data about a particular person become 
known, even just to the researcher handling the data, it would be a serious ethical 
breach. An even greater danger is that personal data leaks to, for instance, the press 
or other unauthorized bodies. This is a real danger that should not be 
underestimated! The sensitive points in the research process include transferring data 
and reporting low frequencies in subgroups that may be traced to a specific person. 
In theory, the ethical review process is a good format for register-based research, but 
the problem is that ethical reviews of studies on human subjects treat all studies more 
or less equally regardless of whether it’s an experimental randomized control trial, a 
purely register-based study (such as study IV) or a study that reuses previously 
collected data (study I, II, IVtw).  For instance, one of the questions on the ethical 
review application concerns potential harms and benefits to participants. For register-
based studies, answering this question becomes a rhetorical exercise. It is my personal 
opinion that register-based research of the kind that only uses registers and no 
researcher-generated primary data should not be treated the same way as clinical 
studies in the ethical review process as the considerations and risk/benefit balance 
becomes artificial. The key is that participants are not strictly participants. Here the 
primary consideration should be about data safety, how leaking and safety breaches 
are prevented, which depends on, for instance, the competence level of those who 
have access to the data. You need a certificate to conduct animal testing but you don’t 
need any formal training to conduct research on sensitive personal data. Also, what 
data is being merged should be considered as some data is more vulnerable than 
other and also may only become vulnerable in combination with other data. It may 
seem paradoxical but the bigger cohort you have, the safer an individual’s data 
actually is. 
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7 MAIN RESULTS AND DISCUSSION 
7.1 VALIDITY OF REGISTER-BASED PARKINSON’S DISEASE AND 
PARKINSONIAN DISORDER CASES (STUDY I) 
Results for validity of register-based parkinsonian disorder and PD case ascertainment 
are shown in fig. 7.1.91 Of all register-based parkinsonian disorder cases who were 
detected in the NPR before the gold standard screening, 88.0% (95% CI 78.4–94.4) 
were confirmed (i.e. the PPV). For the register-based PD cases among these, a lower 
proportion were confirmed; 70.8% (95% CI 58.9–81.0). There were 21 register-based 
PD cases that were misclassified, i.e., not confirmed by the gold standard (the false 
positives) and of these, 13 were diagnosed with a non-PD parkinsonian disorder by the 
gold standard, 4 had other types of movement disorders and 4 were free from 
parkinsonian or movement disorders(fig 7.2). Of these 4, only 1 had not been included 
in the gold standard second screening nor clinical work-up. Thus, almost 30% of 
register-based PD cases in NPR were erroneously classified as PD, but the major cause 
of the errors was misclassification between differential parkinsonian and other 
movement disorders. The proportion of false positive register-based PD cases 
decreased when we restricted the case definition to only include cases with a primary 
PD diagnosis in NPR (PPV 83.0%, 95% CI 70.2-91.9) or only cases who had been 
discharged with a PD diagnosis from specialized hospital departments (PPV 83.3%, 
95% CI 62.6-95.3). As expected, restricting the case definition reduced the sensitivity 
of detection of PD cases from 72.7% to 50.0% when using primary diagnoses and to 
23.5% when using specialized hospital departments. Restricting the case definition by 
excluding all register-based PD cases who also had non-PD parkinsonian disorder 
diagnosis did not improve PPV. Thus, taking into account both PPV and sensitivity, the 
most optimal PD case definition in NPR was to include only cases with primary PD 
diagnoses. However, if the outcome of interest was all parkinsonian disorders, all 
primary and contributory diagnoses in NPR may be used. 
Of 194 parkinsonian disorder cases, 42 (31.6%) died within 3 years from screening and 
among these 17 were correctly given a parkinsonian disorder diagnosis in the CDR, 
with one additional false-positive register-based case, giving a PPV of 94.4% (95% CI 
72.7-99.9) for all parkinsonian disorder cases in CDR. For register-based PD cases in 
CDR the PPV was 66.7% (95% CI 41.0-86.7). Until the end of follow-up in 2008, 127 
parkinsonian disorder cases had died and of these 55 were detected by CDR, giving an 
overall sensitivity of  43.3% (95% CI 34.6-52.4) for all parkinsonian disorders and 57.1% 
(95% CI 45.4-68.4) for PD. Restricting the PD case definition to having a diagnosis as an 
underlying cause of death only improved the PPV to 80.0% (95% CI 28.4-99.5) but 
reduced the sensitivity to 19.5% (95% CI 11.3-30.1). However, only 7.2% of all register-
based cases in NPR and CDR were detected by CDR only and thus the reduced 
sensitivity of PD detection in CDR when restricting the case definition would not affect 
the overall sensitivity in any great way. The low sensitivity in CDR is in line with 
previous reports of underreporting of PD on death certificates.92-95  
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Fig 7.1. Validity of register-based parkinsonian disorder and Parkinson’s disease cases acertained in the 
National Patient Register (on the left) and the Cause of Death Register (on the right), overall and with 
restrictions for definition of Parkinson’s disease cases (Study I). Positive predictive value and sensitivity 
reported as percentages with 95% Clopper-Pearson exact confidence intervals for proportions. CI: 
Confidence interval, PD: Parkinson’s disease, PDS: parkinsonian disorder, PPV: Positive predictive value. 
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In conclusion, the NPR and CDR are valid data sources in epidemiological studies of 
parkinsonian disorders. However, there are certain caveats that researchers should be 
wary of: 
1. Age at first detection of PD or a parkinsonian disorder in NPR is a poor 
estimate of age at onset of the disease. On average, register-based cases were 
first detected 6.8 years (SD 5.5) after the first parkinsonian symptoms 
appeared. This is not surprising as NPR detection is dependent on hospital 
admission and PD is typically treated on an out-patient basis, at least in the 
beginning of the disease. 
2. The reduced sensitivity of register-based detection of PD in particular makes 
the NPR and CDR poor sources of data in studies of occurrence of parkinsonian 
disorders or PD (i.e. overall incidence and prevalence).  
3. If studies depend on differential parkinsonian disorder diagnoses, there will be 
misclassification. By restricting the register-based PD definition 
misclassification can be reduced, but not without reducing the sensitivity of 
detection of an already low-prevalent outcome.  
4. The validity of register-based differential non-PD parkinsonian disorder 
diagnoses such as PSP and CvP is outside the scope of this study, but 
considering the results for PD, the validity may be poor. 
 
Fig 7.2. Gold standard diagnoses among false positive register-based Parkinson’s 
disease cases in the National Patient Register (Study I). Total n=21, number of each 
diagnosis in parenthesis. Solid pieces represent various parkinsonian disorder diagnoses 
whereas patterned pieces represent non-parkinsonian disorder diagnoses. CvP: 
Cerebrovascular parkinsonism, ET: Essential tremor, LBD: Lewy body dementia, PDD: 
Parkinson’s disease dementia, PDS: Parkinsonian disorders, PSP: Progressive 
supranuclear palsy. 
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7.1.1 Methodological Considerations 
We can be fairly certain that all the positive gold standard parkinsonian disorder cases 
are correct, as the clinical work-up was quite rigorous. However, since we did not have 
access to post-mortem neuropathology, there may be uncertainty regarding the 
differential parkinsonian diagnoses. It’s also worth to question how certain we can be 
of the negative gold standard cases. The majority of gold standard parkinsonian 
disorder-free participants were classified as such because they (or their proxy) denied 
having any parkinsonian symptoms in a screening telephone interview. It is possible 
that mild parkinsonian disorder cases could have been missed, and if they were given 
a diagnosis in the registers, they would erroneously be classified as false positives 
which would mean that the PPV was underestimated. However, only 1 of 21 false 
positive register-based PD cases had been classified as a non-case after the first 
screening, all others had been included in the clinical work-up, or at least the second 
telephone screening. We excluded all participants with unclear diagnoses because of 
non-participation in any of the screening phases or clinical work-up. Non-participants 
were on average older than participants. Additional analyses showed that both PPV 
and sensitivity may be lower for older cases, so these measures may have been 
overestimated.  
 
7.2 ASSOCIATION BETWEEN OCCUPATIONAL EXPOSURE AND 
PARKINSON’S DISEASE (STUDY II) 
Results from the study of association between PD risk and occupational exposure are 
shown in fig 7.3.96 There was no association between PD risk and occupational 
exposure to metal dust, wood dust, animal handling, pesticides, stone and concrete 
dust, chrome and nickel dust, quartz dust, organic dust, welding smoke, oil, asbestos, 
organic solvents or irritating gas (HRs ranging from 0.73 to 1.16). For men with any 
probability of inorganic dust exposure there was a significantly increased risk of PD: 
HR 1.63 (95% CI: 1.09-2.44).  
Inorganic dust exposure was found in several occupations including farm workers, 
dental technicians, painters, construction workers, glass workers, dock laborers and 
cleaners. Farmers26,97,98 and cleaners98,99 have previously been associated with PD risk. 
Inorganic dust is a constituent of the particulate matter (PM) in air pollution. Inhaled 
PM may reach not only the systemic circulation but also the central nervous system, 
where it can cause neuroinflammation through the activation of microglia, which are 
found in the substantia nigra of PD patients.100,101 One neuropathological study101 
showed that young adult residents in cities with high air pollution (i.e. Mexico City) 
had neuroinflammation, blood-brain barrier disruption and accumulation of α-
synuclein. It has been hypothesized that α-synuclein-related pathology found in PD is 
possibly initiated in the periphery, for instance via airborne toxin exposure to the 
olfactory epithelium. This is supported by the association between olfactory 
dysfunction and prevalent PD.102 Thus, there is a plausible mechanism through which 
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inorganic dust exposure may increase PD risk. However, it should be considered that 
this may have been a chance finding as when we adjusted for multiple testing using 
the Bonferroni correction for 14 comparisons, the association between inorganic dust 
exposure and PD was no longer significant. 
We found no association between occupational pesticide exposure and PD. Although 
this association is not universally seen, it is fairly well substantiated29,30 and there are 
plausible molecular mechanisms through which it could work, particularly for 
insecticides which by design are often neurotoxic.103 In Sweden, herbicides have been 
more commonly used than insecticides and pesticide use overall has been strictly 
regulated, which could explain the lack of an association in our data. However, other 
Swedish studies have found associations to PD, not with pesticides specifically, but 
with farming as an occupation.26 However, in light of our results, that association with 
farming could be explained at least partially by inorganic dust exposure. 
Fig 7.3. Association between Parkinson’s disease risk and 14 occupational exposures 
(Study II). Total n=14,169. All exposed (any exposure probability level) vs. non-exposed 
as the reference. HRs are from Cox proportional hazard regression models with age as 
the underlying time-scale and adjusted for smoking and education as covariates. HRs 
shown on a log scale. CI: Confidence interval, HR: Hazard ratio. 
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7.2.1 Methodological Considerations 
As the results from Study I (which was performed chronologically after this study) 
showed, restricting the register-based PD case definition by excluding cases who also 
had a non-PD parkinsonian disorder, reduced sensitivity but did not increase PPV of 
PD. Thus, it was not surprising that results were very similar for PD and all 
parkinsonian disorders (see table 3 in published article). We used a JEM to assess 
occupational exposure, which is a useful tool to explore which specific occupational 
aspects may confer risk for a disease. It is also a convenient and sensitive way of 
assessing exposure for a large historical cohort such as in the present study. However, 
as exposure is not assessed on an individual level, the specificity of the exposure 
measure may be low.79,80 Another limitation is that this particular JEM assessed 
probability of any exposure as opposed to actual level of exposure, which may further 
reduce specificity. We used self-reported occupational information from mailed 
questionnaires in the 1960’s and 70’s. A large proportion of men (25.0%) were missing 
information on occupation, which reduced our power. If we had repeated the study 
today we may have used the 1970 census as the source of occupational data instead 
which may have reduced missingness. We adjusted the analyses for age, sex, smoking 
status at baseline and educational level. However, as is shown in the DAG in fig. 5.4, 
smoking and education are not clear-cut confounders of the association between 
occupational exposure and PD. Smoking has an effect on PD risk, but the causal 
pathway between smoking and occupational exposure is less clear. What is certain is 
that smoking does not “cause” occupation, however, occupation may “cause” 
smoking, in which case smoking is a mediator between occupation and PD. Most likely 
there is unmeasured confounding (“U”) which causes both smoking and occupation, 
and it’s plausible that at least part of this confounding is captured by adjusting for 
education. Education on its own is certainly causally associated with occupation, but 
perhaps the only association between education and PD is through occupation, in 
which case education is not a confounder and should not have been adjusted for.  
 
7.3 FAMILIAL AGGREGATON OF PARKINSON’S DISEASE  
(STUDY IV, IVtw) 
Results for familial aggregation of all parkinsonian disorders and PD in all first-degree 
relatives, siblings, parent-offspring, twins and spouses are shown in fig 7.4.89  As 
expected, there was a clear indication of a trend of greater familial aggregation 
associated with higher genetic correlation (MZ > DZ > Siblings > Parent-offspring > 
Spouses), although the estimate for DZ twins appeared to be somewhat lower than 
expected. One explanation could be the younger age range in the siblings compared 
to the twins as it’s likely that familial aggregation is more commonly observed in 
families of young onset cases. Nevertheless, the results add to evidence from several 
previous studies, including those on the same data as here,16,104 supporting strong 
familial aggregation of PD and parkinsonian disorders overall.17 
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Similarly strong familial risks were found for AD and dementia, although there was not 
as clear a trend of genetic correlation as for parkinsonian disorders and PD. The 
highest estimate for familial aggregation in AD was among siblings (HR 5.79, 95% CI 
4.84-6.92). AD is likely affected more than PD by the right truncation at age 78 of the 
cohort and this could explain why the siblings show such high familial risks. 
Interestingly, there was a slight significant familial risk of AD among spouses (HR 1.07, 
95% CI 1.03-1.10). This association could be explained by correlation in educational 
level among spouses. 
 
7.4 CO-OCCURRENCE OF PARKINSONISM AND DEMENTIA  
(STUDY IV, IVtw) 
Among all participants in Study IV (all persons in the first-degree relative and spouse 
cohorts, born 1890-1960), there were 15,048 individuals who had co-occurring 
dementia and parkinsonian disorders, corresponding to 23.4% of parkinsonian 
disorder cases or 5.7% of dementia cases. There was a strong association between PD 
status and risk of co-occurring dementia (HR 2.83, 95% CI 2.76-2.89). Among the twins 
(Study IVtw) there were 195 dementia cases among 882 PD cases (22.1%), with a 
similar association between PD status and risk of co-occurring dementia (HR 2.23, 95% 
CI 1.92-2.60). These estimates are similar to what others have found.46 Undoubtedly 
the association between PD and dementia in individuals is strong. 
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Fig 7.4. Results for familial aggregation of Parkinson’s disease, all parkinsonian disorders, Alzheimer’s 
disease and all dementia (Study IV, IVtw). Association between disease risk and having an affected relative, 
overall and by relative type. All FDR refers to siblings and offspring in parent-offspring comparisons. All FDR 
born 1932-1960 and followed 1972-2009, Spouses born 1890-1960 and followed 1969-2009, twins born 1886-
1958 and followed 1974-2010. HRs shown on a log scale. CI: Confidence interval, DZ: Dizygotic, FDR: First-
degree relatives, HR: Hazard ratio, MZ: Monozygotic, Par-offspr.: Parent-offspring. 
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7.5 FAMILIAL COAGGREGATION OF PARKINSON’S DISEASE AND 
DEMENTIA (STUDY III, IV, IVtw) 
Results for dementia risk associated with family history of PD and parkinsonism risk 
associated with family history of AD are shown in fig. 7.5 (study IV, IVtw). When 
dementia was the outcome there was no association with family history of PD for 
parent-offspring, twins or spouses, but there was a modest significant association for 
siblings, HR 1.20 (95% CI 1.02-1.41). However, as the power was higher in the parent-
offspring analysis, the sibling association did not make a large impact on the result for 
all first-degree relatives. When parkinsonism was the outcome the association in 
siblings was somewhat stronger, HR 1.35 (95% CI 1.11-1.65). There was also an 
association of similar magnitude between parkinsonism risk and having a parent with 
AD, HR 1.21 (95% CI 1.13-1.29). As expected, there was no association among spouses 
in either direction. According to the assumptions we have made about the causal 
pathways between risk of dementia or PD and family history of the opposite disease, 
we would expect the association to be similar in both directions and thus the different 
results depending on direction for parent-offspring analyses is puzzling. In parent-
offspring analyses the family history exposure was ascertained among the parents 
Fig 7.5. Results for familial coaggregation of Parkinson’s disease and dementia (Study IV, IVtw). Association 
between dementia risk and having a relative with PD (left) and association between parkinsonism risk and 
having a relative with AD (right), overall and by relative type. All FDR refers to siblings and offspring in parent-
offspring comparisons. All FDR born 1932-1960 and followed 1972-2009, Spouses born 1890-1960 and 
followed 1969-2009, twins born 1886-1958 and followed 1974-2010. HRs shown on a log scale. AD: 
Alzheimer’s disease, CI: Confidence interval, DZ: Dizygotic, FDR: First-degree relatives, FH: Family history, HR: 
Hazard ratio, MZ: Monozygotic, Par-offspr.: Parent-offspring, PDS: Parkinsonian disorders. 
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who were not subjected to the same right censoring as their offspring in whom the 
outcome was ascertained. Therefore the parent history exposure better represents 
the onset age spectrum in both dementia and parkinsonism. However, parkinsonism 
has an earlier onset than dementia and as was shown in fig. 5.8, the parkinsonism 
cases in the first-degree relative cohort seem to better represent the overall case 
population than the dementia cases who obviously represent a young onset case 
population. Perhaps the risk of dementia associated with family history of PD is not 
apparent among young onset dementia cases and thus we would have to follow the 
offspring for an additional 10-20 years before the results are comparable in both 
directions. On the other hand, if we were to follow the cohort in older ages it would 
become more and more similar to the twin cohort, in which no associations were 
shown indicating that perhaps the sibling associations could only be found in a 
younger population.  
Results for meta-analysis of cohort and case-control studies on dementia risk 
associated with family history of PD are shown in fig 7.6105 (Study III, IV). Before adding 
the estimate from Study IV to the meta-analysis, the meta-estimate was pointing 
towards a conclusion in support of a modest familial coaggregation of PD and 
dementia, just as Study IV did overall. However, as described above, there was no 
association for familial aggregation among parent-offspring in Study IV and this 
association drove the estimate for all first-degree relatives to also show no 
association, despite the small but significant association among siblings. So, when the 
estimate from study IV for first-degree relatives was added to the meta-analysis, as 
indeed it would have been if we had published study IV before commencing the data 
collection for study III, the conclusion of Study IV is changed to that there is no 
evidence, not even of a modest association, in support of familial coaggregation of PD 
and dementia.  
But what about among siblings, where there was an association in study IV? When 
adding the sibling estimate from study III to the other published estimates for 
dementia risk associated with family history of PD among siblings, the meta HR was 
1.17 (95% CI 1.02-1.36, I2: 0.0%, p=0.942, weight of study IV = 79.5%). However, when 
the estimates from Study IVtw, which did not show any association (twins are siblings 
after all), were also added, these counteracted the estimate from study IV and the 
resulting meta-estimate was of no association (fig 7.7). As the population in study IVtw 
overlaps partly with the siblings of Study III, these estimates should not strictly 
speaking be entered together in the same meta-analysis, or their weights should be 
reduced to account for the dependence of the data. Nevertheless, the conclusion 
must be that the meta-analysis of familial coaggregation of PD and dementia among 
siblings does no longer indicate any significant association when all data are 
combined. 
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A funnel plot of all cohort and case-control studies of dementia risk associated with 
first-degree family history of PD is shown in fig 7.8. When all data were included (all 
studies originally included in study III plus the estimate from study IV and Boot 
(2013)), there appears to be funnel plot asymmetry indicating a small study effect, or, 
as it is otherwise called, publication bias. However, considering the cohort studies and 
case-control studies separately there was no evidence of publication bias; Egger’s test 
of funnel plot asymmetry p=0.275 and 0.232, respectively. The choice to show all 
cohort and case-control studies together in the same funnel plot was made to 
illustrate how the cohort studies were consistently more powerful but the case-
control studies on average produced higher estimates of association.  
Fig 7.6. Forest plot depicting meta-analysis of studies of dementia risk associated with first-degree 
family history of Parkinson’s disease (Study III with added data from study IV and Boot (2013)). 
Note that cohort studies estimate HRs and case-control studies estimate ORs. Estimates shown on 
log scale. The grey boxes around each estimate illustrate the relative sample size of each study, 
which is proportional to the weight. Without the added estimate from Study IV to the cohort studies 
the meta HR was 1.20 (95% CI 1.03-1.40, I2: 0.0%, p=0.513). Without the added estimate from Boot 
(2013) to the case-control studies the meta OR was 1.40 (95% CI 0.92-2.12, I2: 1.3%, p=0.414). CI: 
Confidence interval, HR: Hazard ratio, OR: Odds ratio. 
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Thus, considering studies III, IV and IVtw together, the overall conclusion is that there 
may be no familial coaggregation of PD and dementia. Or if there is, it is of a very 
modest magnitude and perhaps only present among young onset cases. Indeed, if it is 
there it is so small that the only clinical significance of this result is that families of PD 
patients may know that their family history probably does not put them at an 
increased risk of dementia and clinicians may know that family history of either PD or 
dementia is not a useful biomarker for the diagnosis of the opposite disease.  
But why is the magnitude of the associations for familial coaggregation so small (or 
not there at all)? Under the assumption that the DAG in fig 5.10 represents the true 
underlying causal pathways between PD and dementia in families and that all 
pathways have positive effects (fig 7.9a), we would expect to see an association 
between PDR and Dementia, even if we are wrong about there being shared familial 
risk (FPD/Dementia) (fig 7.9b). This because there is an open path going 
Fig 7.7. Forest plot depicting meta-analysis of cohort studies of dementia risk associated with first-
degree family history of Parkinson’s disease (Study III with added data from studies IV and IVtw). 
Estimates shown on log scale. The grey boxes around each estimate illustrate the relative sample 
size of each study, which is proportional to the weight. Without the added estimates from Studies IV 
and IVtw to the sibling risk analysis the meta HR was 1.07 (95% CI 0.78-1.47, I2: 0.0%, p=0.995). 
Without the added estimate from Study IV to the parent-offspring risk analysis the meta HR was 
1.34 (95% CI 0.89-2.02, I2: 67.7%, p=0.026). CI: Confidence interval, HR: Hazard ratio. 
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PDRFPDPDDementia and there is a strong association between PDR and PD, and 
between PD and comorbid Dementia. The absence of an association between PDR and 
Dementia (or the fact that the association is so modest) leads us to think that the DAG 
may be wrong. But wrong in which way? There are several options: 
i. Perhaps there is no direct causal pathway PDDementia (and 
PDRDementiaR) (fig 7.9c). Then, since the path between PD and Dementia 
though C is blocked in the collider at PD, FPD/Dementia is the only remaining open 
path and then the observed weak association or no association is a true effect. 
However, is it plausible that there is no direct effect of PD on dementia and 
that the whole association between PD and comorbid dementia is due to a 
non-shared familial confounding (C)? In light of the neuropathological and 
molecular evidence, this does not seem likely. For instance, α-synuclein is a 
precursor to the non-amyloid component of amyloid-β plaques, and may, 
when abundant, thus promote dementia-related pathology.106,107 
Perhaps one of the pathways is actually an inverse association which counteracts the 
effect of FPD/Dementia making it appear as a weak association between PDR and 
Dementia? Let’s explore which pathway could be inverse: 
Fig 7.8. Funnel plot with 95% pseudo confidence intervals of all studies of dementia risk associated with 
first-degree family history of Parkinson’s disease (Study III with added data from study IV). Note that 
cohort studies estimate HR and case-control studies estimate OR. The overall meta-estimate represented 
by the vertical line was 1.11 (95% CI 1.00-1.22). Without the added estimated from Boot (2013) and Study 
IV the overall meta-etimate was 1.20 (95% CI 1.03-1.41) and p=0.244 for funnel plot assymetry. HR: Hazard 
ratio, OR: Odds ratio, SE: Standard error. 
Egger’s test for funnel plot 
asymmetry p=0.029. 
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ii. If PDDementia (and PDRDementiaR) was inverse, meaning that the 
presence of PD actually decreased the risk of dementia, it could counteract the 
effect of FPD/Dementia and the association between PDR and Dementia would 
disappear or appear weak (fig 7.9d). However, this is not a likely explanation 
due to the evidence for a positive causal effect listed above and the fact that C 
would then have to be super strong to counteract the inverse causal effect of 
PDDementia since the association between PD and Dementia is so strong. 
iii. One of the pathways FPD/DementiaPD/FPD/DementiaPDR or 
FPD/DementiaDementia/ FPD/DementiaDementiaR could be inverse, meaning that 
the effect of FPD/Dementia is an increased risk of one of the diseases and a 
decreased risk of the other disease which would appear as a net effect of no 
association or very weak association between PDR and Dementia (fig 7.9e). 
This is actually the most likely model, and the results from the spouse risk 
analyses support it. Firstly, within PD the HR for spouses was 1.07 (95% CI 
0.98-1.17, fig 7.4), which is not significant but may point towards the existence 
of a weak environmental FPD among spouses. However, there was a slight 
negative association between PDR and Dementia among spouses, HR 0.96 
(95% CI 0.93-0.99). Again, the association is very weak but it’s notable that it’s 
in the opposite direction, as if some pathway is counteracting the effect of FPD. 
And that could be the presence of an environmental FPD/Dementia which weakly 
increases risk of PD while decreasing risk of Dementia. In fact, there are two 
possible environmental risk factors that may have this effect and that are 
correlated in families; nonsmoking108,109 and higher education.25,110 
 
7.5.1 Methodological Considerations 
The greatest methodological problem in Study IV is short follow-up age-wise. As 
shown in the lexis-diagrams (fig 5.9), follow-up in the first-degree relative cohort was 
only until 78 years for the oldest of the cohort. To grasp the impact of this right 
censoring we can compare age-specific incidence rates of disease in the first-degree 
relative cohort to the twin cohort which was followed to a theoretical age of 124 (fig. 
5.9). For PD and parkinsonian disorders, many cases are missed after age 78, but the 
younger cases do not seem to be unusually young as incidence does not increase that 
dramatically after 78. For dementia however, a very small proportion of cases are 
detected before age 78 and it is apparent that these cases are not representative of 
typical dementia cases in the population. The impact of this censoring is thus that 
when dementia was the outcome, it was really young onset dementia specifically. It is 
possible that the association would have been lost if we had been able to follow the 
cohort for as long as the twin cohort. Unfortunately we could not test to see if a sub 
cohort of the twin cohort with the same follow-up as the first-degree relative cohort 
would also show an association due to too low power. Lastly, the imperfect sensitivity 
of the register-based ascertainment may have caused non-defferential 
misclassification and bias towards the null.  
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Fig 7.9a-e. Directed acyclical graphs representing different causal models for the association 
between first-degree family history of PD and dementia (Study III, IV, IVtw). DAG adapted 
from Hudson et al.59 FPD: Familial risk factors for PD, FDDementia: Familial risk factors for 
dementia, FPD/Dementia: Familial risk factors common to PD and Dementia, C: Non-shared risk 
factors for both PD and Dementia, PD: Parkinson’s disease. 
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8 CONCLUSIONS 
I. Parkinson’s disease and parkinsonian disorder register-based case 
ascertainment in the national patient and Cause of Death Registers is valid for 
use in epidemiological studies, although not perfect. The most optimal case 
definition is achieved when using primary hospital discharge diagnoses.  
 
II. Occupational exposure to inorganic dust may be a risk factor for Parkinson’s 
disease in Swedish men who were of working age in the 1960’s and 1970’s. In 
this population, there may not be any association between Parkinson’s disease 
risk and occupational exposure to metal dust, wood dust, animal handling, 
pesticides, stone and concrete dust, chrome and nickel dust, quartz dust, 
organic dust, welding smoke, oil, asbestos, organic solvents and irritating gas. 
 
III. There may be an association of modest magnitude between dementia risk and 
positive first-degree family history of Parkinson’s disease, indicating the 
presence of familial coaggregation of these disorders. 
 
IV. There is an association of modest magnitude between dementia risk and 
positive family history of Parkinson’s disease among siblings, but not among 
parents-offspring, and an association between parkinsonian disorder risk and 
positive family history of Alzheimer’s disease in siblings and parents-offspring. 
In monozygotic or dizygotic twins there may not be any familial coaggregation 
of Parkinson’s disease and dementia. 
There is strong familial aggregation among siblings and parents-offspring for 
parkinsonian disorders overall, Parkinson’s disease, dementia overall and 
Alzheimer’s disease. 
Separately, the results from study III and study IV indicate that there is familial 
coaggregation of Parkinson’s disease and dementia, whereas the results from 
study IVtw are inconclusive. However, when the results from all three studies 
are pooled there is no longer any association between Parkinson’s disease and 
dementia, and the conclusion is that there may not be familial coaggregation 
of these disorders. 
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9 STRESZCZENIE PO POLSKU 
Ruchy ciała ludzkiego wykonywane są przez mięśnie sterowane impulsami wysyłanymi 
z ośrodkowego układu nerwowego za pośrednictwem układu nerwowego 
obwodowego. Olbrzymia ilość komórek nerwowych tworzących układ nerwowy, 
zarówno obwodowy jak i ośrodkowy, łączy się ze sobą w rozległą sieć. Każda 
pojedyńcza komórka nerwowa składa się z pękatego ciała komórkowego 
zawierającego jądro komórkowe oraz z krótkich i długich wypustkach zwanych 
dendrytami i aksonami. Komórki nerwowe komunikują się ze sobą wysyłając związki 
chemiczne – neuroprzekaźniki. Cząsteczki neuroprzekaźników, wydzielane przez 
wypustki nerwowe jednej komórki, reagują z receptorami znajdującymi się na 
powierzchni sąsiadującej komórki nerwowej. 
Na najwyszej części pnia mózgowego znajduje się obustronnie rozmieszczone, 
wydłużone blaszkowate ciało zwane istotą czarną (substantia nigra). 
Wyspecjalizowane komórki nerwowe istoty czarnej wytwarzają neuroprzekaźnik 
dopaminę, której funkcją jest między innymi inicjonowanie i koordynacja ruchów w 
ośrodkowym układzie nerwowym. Zwyrodnienie tych właśnie komórek nerwowych, 
powodujące z kolei lokalne zakłócenia w wydzielaniu dopaminy, jest głównym 
czynnikiem ograniczenia sprawności ruchowej, a tym samym patogonezy choroby 
Parkinsona.  
Objawy choroby Parkinsona są drżenie spoczynkowe (tremor), sztywność mięśniowa 
oraz spowolnienie i zubożenie ruchów. Objawy pojawiają się zwykle po jednej stronie 
ciała i narastają powoli i stopniowo. Po pewnym czasie choroba prowadzi do 
poważnego inwalidztwa. Ryzyko zachorowania zwiększa się z wiekiem i jest największe 
po 65 roku życia. Choroba Parkinsona dotyka około 1% populacji. 
Dotychczas odkryto kilka genów, zmiany w których wiąże się obecnie ze zwiększonym 
ryzykiem występowania choroby Parkinsona. Przypadki, kiedy chorobę można 
przypisać wyłącznie czynnikom genetycznym, zdarzają się jednak bardzo rzadko. W 
większości wypadków wystąpienie choroby Parkinsona następuje w wyniku 
wzajemnego oddziaływania zarówno czynników genetycznych, jak i środowiskowych. 
Jeżeli chodzi o czynniki środowiskowe, tylko niektóre udało się jak dotąd 
zidentyfikować. Do tych, o których wiemy, że mają istotny związek z choroba 
Parkinsona, należy palenie tytoniu, które wykazuje działanie ochronne, tzn. – palacze 
mają mniejsze ryzyko zachorowania niż osoby niepalące. Wśród innych dotychczas 
zbadanych czynników środowiskowych, które przypuszczalnie zwiększają ryzyko 
zachorowania, są między innymi biocydy używane w rolnictwie, produkty mleczne, 
oraz metale. 
Poza ograniczoną zdolnością ruchową, chorzy na chorobę Parkinsona wykazują 
również inne objawy neurologiczne, takie jak otępienie (demencja) czyli zaburzenie 
procesów poznawczych obejmujących funkcje pamięci, koncentracji oraz myślenia i 
rozumienia. Dlaczego chorzy na Parkinsona cierpią również na otępienie? Dwie 
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przyczyny uważa się za najbardziej prawdopodobne: 1) Uszkodzenie komórek 
nerwowych, znajdujących się w śródmózgowiu i wytwarzających dopaminę, 
rozprzestrzenia się również do innych części mózgu, które kierują procesami 
poznawczymi; 2) Te same – dziedziczne lub środowiskowe – czynniki, które powodują 
neurodegenerację w śródmózgowiu, prowadzą również do neurodegeneracji w innych 
częściach mózgu związannych z czynnościami poznawczymi. 
Ogólnym celem niniejszej rozprawy doktorskiej jest lepsze poznanie przyczyn choroby 
Parkinsona oraz lepsze zrozumienie powodów, dla których u pacjentów cierpiących na 
chorobę Parkinsona pojawia się równiez otępienie. 
Wiele badań epidemiologicznych, które przeprowadza się zarówno w Szwecji, jak i w 
innych krajach, opiera się na danych gromadzonych do innych celów niż cele naukowe 
– na przykład dane gromadzone w rejestrach administracyjnych służby zdrowia. 
Dlatego powinno się zbadać, jak należy używać danych z tego typu rejestrów w 
badaniach naukowych. W części I niniejszej pracy przedstawione zostały wyniki 
badania przydatności diagnoz choroby Parkinsona, znajdujących się w szwedzkim 
Rejestrze Pacjentów i Rejestrze Przyczyn Zgonów, do badań epidemiologicznych. 
Diagnozy zawarte w Rejestrze Bliźniąt zostały potraktowane jako złoty standard, czyli 
jako najlepsze dostępne diagnozy. W Rejestrze Bliźniąt zgromadzone są dane z 
obszernych badań przeprowadzonych w Szwecji w latach 1998–2004 na ponad 35 
tysiącach bliźniąt w wieku 50 lat i więcej.   
Rezultaty wykazują, że z zarejestrowanych w Rejestrze Pacjentów przypadków, kiedy u 
pacjenta zdiagnozowano chorobę Parkinsona w wyniku przynajmniej jednego pobytu 
w szpitalu, aż 83% można było potwierdzić przez złoty standard (dodatnia wartość 
predykcyjna). Jeżeli chodzi o Rejestr Przyczyn Zgonów, 80% przypadków zostało 
potwierdzonych. Większość osób, których choroba została błędnie zarejestrowana, 
cierpiało na choroby, które, podobnie jak choroba Parkinsona, atakują aparat ruchowy 
(parkinsonizm). Czułość rejestru wynosi 50%, co oznacza, że ze wszystkich przypadków 
choroby Parkinsona (według złotego standartu), połowa została zarejestrowana 
również w Rejestrze Pacjentów przynajmniej jeden raz w czasie życia chorego. 
W części II rozprawy zbadany został związek pomiędzy ryzykiem zachorowania na 
chorobę Parkinsona a czternastoma różnymi czynnikami ekspozycji zawodowej w 
grupie ponad 14 tysięcy męskich bliźniąt. W latach 1960-tych i 1970-tych uczestniczyli 
oni w badaniach ankietowych i dane o nich, uzupełnione danymi zawartymi w 
szwedzkich rejestrach służby zdrowia i zbieranymi przez okres następnych 43 lat, 
pozwoliły na przeprowadzenie niniejszych badań. Stopień narażenia osób badanych 
został zmierzony za pomocą matrycy szacującej ryzyko zawodowe (tzn. w zależności 
od zawodu wykonywanego przez osobę badaną) ekspozycji na różne substancje 
chemiczne. Rezultaty wykazały, że wśród tych, którzy byli narażeni na pyły 
nieorganiczne, nastąpiło zwiększenie ryzyka choroby Parkinsona o 63% (współczynnik 
hazardu 1,63 (przedział ufności 1,09–2,44)). Do grupy substancji określanych jako 
„pyły nieorganiczne” zalicza się między innymi pył drogowy, podnoszący się w 
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miejskim ruchu ulicznym. Powyższy rezultat został otrzymany po raz pierwszy i 
powinien w związku z tym stać się przedmiotem dalszych badań. Żaden związek nie 
został natomiast zaobserwowany w przypadku pozostałych trzynastu czynników 
ekspozycji zawodowej na substancje chemiczne, takich jak na przykład biocydy 
używane w rolnictwie. 
Celem analiz przedstawionych w części III i IV niniejszej pracy było zbadanie, czy 
istnieją rodzinne czynniki dziedziczne i/lub środowiskowe (na przykład z powodu 
podobnego stylu życiu w rodzinie, itp.), mogące spowodować zarówno chorobę 
Parkinsona jak i otępienie. Jednym ze sposobów podejścia do tego problemu było 
zbadanie, czy choroby tego typu gromadzą się w rodzinach – innymi słowy, czy krewni 
pierwszego stopnia (rodzeństwo biologiczne lub rodzice i dzieci) chorują na obie te 
choroby równocześnie częsciej, niż można byłoby tego oczekiwać. W analizie zostały 
porównane ryzyka zachorowania na chorobę X u ludzi, w których rodzinach są osoby 
chorujące na chorobę Y lub w których rodzinach ta choroba (Y) nie występuje. 
Część III jest publikacją przeglądową, gdzie została przedstawiona metaanaliza 
rezultatów z 16 publikacji badających albo a) związek pomiędzy ryzykiem otępienia a 
występowaniem choroby Parkinsona u członków najbliższej rodziny, albo b) związek 
pomiędzy ryzykiem choroby Parkinsona a występowaniem otępienia w rodzinie.  
W części IV zostały przedstawione wyniki badania związków (a) i (b) wśród ponad 2 
miljonów mieszkańców Szwecji. W badaniu wykorzystano dane o związkach 
pokrewienstwa z Rejestru Pokoleń oraz dane o stanie zdrowia z rejestrów służby 
zdrowia. Rezultaty badania z części III wykazały, że osoby mające krewnych pierwszego 
stopnia cierpiących na chorobę Parkinsona mają, ogólnie rzecz biorąc, zwiększone o 
18% ryzyko zachorowania na otępienie w porównaniu z tymi, u których w rodzinie 
otępienie nie występuje (współczynnik hazardu 1,18 (przedział ufności 1,00-1,39)). 
Rezulty badania w części IV pokazują, że u osób, których biologiczne rodzeństwo cierpi 
na chorobę Parkinsona, ryzyko zachorowania na otępienie zwiększa się o 20% 
(współczynnik hazardu 1,20 (przedział ufności 1,02-1,41)). 
Z przedstawionych tu rezultatów należy wysnuć wniosek, że istnieje niewielka 
akumulacja tych dwóch chorób w rodzinach. To również oznacza, że nawet jeżeli jest 
prawdopodobne, że choroba Parkinsona i otępienie mają wspólne rodzinne czynniki 
ryzyka, nie mogą owe czynniki w pełni wytłumaczyć dlaczego pacjenci cierpiący na 
chorobę Parkinsona również w tak wysokim stopniu sami cierpią na otępienie. 
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10 AFTERWORD 
The historically relatively recent and dramatic improvement in life expectancy in 
world-wide is a truly striking image (fig. 10.1). This is the result of reforms in 
economic, social and medical conditions and it’s an immensely positive development. 
However, there are also serious challenges. For instance, concerning social and 
economic conditions, an increasing number of persons need to be supported in old 
age. In the medical field, an increasing number of persons will live with chronic aging-
related diseases as the 
relative and absolute 
population at risk of 
these diseases grows. 
We need more basic 
research to understand 
what is happening with 
these diseases in the 
population and if we are 
ever going to have a 
chance to actively 
prevent them. Luckily, it 
appears that at least for 
dementia the incidence 
may be decreasing as 
this was reported by 
two recent papers from 
England111 and 
Sweden.112  
 
10.1 ERRATA 
No thesis is perfect and that certainly includes this one. Before even sending it to the 
printers I can already report two formatiing errors: 
• Paper II 
There is an error in the column headings of tables 2 and 3, the correct 
headings should read: N; IR/100,000 PYR; HR; 95% CI. 
• Paper IV 
The columns are misaligned in the bottom part of table 1. 
If any more errors are discovered after the publication of the 
thesis I will post them online at this address: http://goo.gl/Q4kxed 
(also accessible through the QR-code). 
Fig. 10.1. Life expectancy at birth in Sweden from 1800 to 
2012 as well as status in 2012 of life expectency in the rest 
of the world’s countries (seen on the right). Source: Free 
material from www.gapminder.org. 
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“ Why, anybody can have a brain.  
That's a very mediocre commodity.  
Every pusillanimous creature that crawls on the 
earth or slinks through slimy seas has a brain. 
Back where I come from, we have universities, 
seats of great learning, where men go to become 
great thinkers. 
And when they come out, they think deep 
thoughts and with no more brains than you have.  
But they have one thing you haven't got:  
A diploma. ” 
-The Wizard, The Wizard of Oz (1939) 
Portrait of the author by Jorge Cham (2011) 
